



GB 04/1687

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 24 MAY 2004

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *R. McHoney*
Dated 13 May 2004

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

Its Form 1/77

Act 1.
)

Request for grant of a patent

Notes on the back of this form. You can also obtain an explanatory leaflet from the Patent Office to fill in this form)

THE PATENT OFFICE

25 APR 2003

RECEIVED

The
Patent
Office

1/77

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Your reference

P033963GB/PNH/SMT

28APR03 E802895-8 D00019
P01/7700 0.00-0309506.4

Patent application number

(The Patent Office will fill in this part)

25 APR 2003

0309506.4

Full name, address and postcode of the or of
each applicant (underline all surnames)

University College Cardiff Consultants Limited

56 Park Place

P.O. Box 497

Cardiff

CF1 3XR

(For further applicants please see continuation sheet)

FILED
00798603009

Patents ADP number (if you know it)

If the applicant is a corporate body, give the
country/state of its incorporation

GB

Title of the invention

Chemical Compounds

Name of your agent (if you have one)

Carpmaels & Ransford

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

43 Bloomsbury Square
London
WC1A 2RA

Patents ADP number (if you know it)

83001

If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)

Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body

Yes

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	1
Description	47
Claim(s)	6
Abstract	0
Drawing(s)	0

mc

10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (<i>Patents Form 7/77</i>)	-
Request for preliminary examination and search (<i>Patents Form 9/77</i>)	1
Request for substantive examination (<i>Patents Form 10/77</i>)	-
Any other documents (please specify)	-

11. I/We request the grant of a patent on the basis of this application.

Signature	Date
<i>Carpmaels & Ransford</i>	25th April 2003
Carpmaels & Ransford	

- | | | |
|--|--------------|---------------|
| 12. Name and daytime telephone number of person to contact in the United Kingdom | Susan Thomas | 020-7242 8692 |
|--|--------------|---------------|

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Rega Foundation
Minderbroedersstraat 10
B-3000 Leuven
Belgium


78935891001

country/state of incorporation BE

Chemical Compounds

The present invention relates to a chemical compound and to its therapeutic use in the prophylaxis and treatment of viral infection for example human herpes viruses, particularly
 5 and human cytomegalovirus (HCMV). Cytomegalovirus is the aetiological agent in CMV retinitis and other viral infections, which can cause considerable human illness and suffering.


We have previously noted that nucleoside analogues of the structural types 1 and 2 exhibit
 10 a potent and selective antiviral effect (McGuigan *et al* J. Med. Chem. 1999, 42, 4479-84 and J. Med. Chem. 2000, 43, 4993-97):



15 Optimal structures are 1, R=C8-C10 and 2, R=pC₅Ph. Further details are given in WO 98/49177 and WO 01/83501, respectively. The compounds exclusively inhibit Varicella zoster virus (VZV) in a VZV – thymidine-kinase dependent fashion, functioning in a classical nucleoside analogue manner, of obligate intracellular nucleoside kinase-mediated activation (Balzarini *et al*, Mol. Pharmacol. 61, 249-254, 2002).

20

We have recently noted that dideoxynucleoside analogues of 1 have a pronounced but quite distinct activity against another member of the herpes family, namely human cytomegalovirus HCMV. The optimal structure of these agents was identified as 3 and is
 25 described in WO 01/85749.




These agents would have been expected to act via a classical nucleoside mechanism, requiring 5'-phosphorylation before they would exhibit antiviral activity. As such a 5'-OH and a quasi-nucleoside structure with a sugar or close analogue was deemed necessary.

5 It is an object of the present invention to provide novel compounds, in particular novel compounds not requiring phosphorylation for, for example, biological activity.

It is a further object of the present invention to provide novel compounds for therapeutic use in the prophylaxis and treatment of viral infection, for example, by cytomegalovirus.

10

According to the present invention there is provided a chemical compound having the formula (I):



wherein:

15

R¹ and R⁴ are independently selected from alkyl, aryl, alkenyl and alkynyl;

Z is selected from O, NH, S, Se, NR⁵ and (CH₂)_n where n is 1 to 10, and CT₂ where T may be the same or different and is selected from hydrogen, alkyl and halogens, and R⁵ is alkyl, alkenyl or aryl;

20

Y is selected from N, CH and CR⁶ where R⁶ is alkyl, alkenyl, alkynyl or aryl;

Q is selected from O, S, NH, N-alkyl, CH₂, CHalkyl and C(alkyl)₂;

25

U is selected from N and CR² where R² is selected from hydrogen, alkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkoxy, aryloxy, thiol, alkylthiol, arylthiol and aryl;

V is selected from N and CR^3 where R^3 is selected from hydrogen, alkyl, halogens, alkyloxy, aryloxy and aryl;

5 and when a double bond exists between X and the ring atom to which Q is attached and Q is linked to the ring moiety by a single bond, X is selected from N, CH and CR^7 , where R^7 is selected from alkyl, alkenyl, alkynyl and aryl; and

10 when a double bond links Q to the ring moiety and a single bond exists between X and the ring atom to which Q is attached, R^4 does not exist and X is NR^8 , where R^8 is alkyl, alkenyl, alkynyl or aryl, except that when Y is N, U is CR^2 and V is CR^3 , R^8 is not an alkyl or alkenyl group substituted at the fourth atom of the chain of said alkyl or alkenyl group, counted along the shortest route away from the ring moiety including any hetero atom present in said chain, by a member selected from OH, phosphate, diphosphate, 15 triphosphate, phosphonate, diphosphonate, triphosphonate and pharmacologically acceptable salts, derivatives and prodrugs thereof;

and pharmacologically acceptable salts, derivatives and prodrugs of compounds of formula (I).

20

Surprisingly the dideoxysugar in prior art compounds known from WO 01/85749 (structure 3 above) can be replaced by an alkyl, alkenyl, alkynyl or aryl moiety that does not require phosphorylation for biological activity and hence does not require the hydroxy or any groups on the, for example, alkyl C_4 atom deemed necessary for phosphorylation.



25

Preferably neither R^4 nor R^8 contains any suitable hydroxy group that may be subject to biological phosphorylation. In particular, preferably neither R^4 nor R^8 is a ribose, deoxyribose, dideoxyribose, dideoxydidehydroribose sugar or similar sugar group or close analogue.

30

Compounds having a double bond between X and the ring atom to which Q is attached are isomers of compounds having a single bond between X and the ring atom to which Q is attached. Compounds having a double bond between X and the ring atom to which Q is

attached are entirely non-nucleosidic in nature. Examples of these two isomers are, for instance, structures 4 and 5:



5

Varying the composition of R^1 , R^4 and R^8 of formula (I) determines the biological activity of the compounds.

10 Preferably Z is O or NH. Where Z is N-alkyl, suitably the alkyl is C_1 to C_5 alkyl.

Preferably Y is N.

15 Preferably Q is CH_2 , S or O. More preferably Q is O. Where Q is N-alkyl, suitably the alkyl is C_1 to C_5 alkyl. Where Q is CHalkyl or $C(alkyl)_2$, suitably the alkyl is C_1 to C_5 alkyl.

Preferably each of U and V is CH.

20 When a double bond exists between X and the ring atom to which Q is attached, X and Y are preferably both N.

When a double bond exists between X and the ring atom to which Q is attached, Z is preferably O.

25 When a double bond exists between X and the ring atom to which Q is attached, Q is preferably O.

When X and Y are N, Q and Z are independently preferably selected from O, S and NH, more preferably Q and Z are O.

Throughout the present specification:

5

alkyl includes cycloalkyl, alkyl substituted with cycloalkyl, alkyl containing within the alkyl chain 1, 2, 3 or 4 heteroatoms selected independently from O, S and N, substituted alkyl and branched alkyl;

10 alkenyl includes cycloalkenyl, alkyl substituted with cycloalkenyl, alkenyl containing within the alkenyl chain 1, 2, 3 or 4 heteroatoms selected independently from O, S and N for example tetrahydrofuran (THF), substituted alkenyl and branched alkenyl;

alkynyl includes cycloalkynyl, alkyl substituted with cycloalkynyl, alkynyl containing
15 within the alkynyl chain 1, 2, 3 or 4 heteroatoms selected independently from O, S and N, substituted alkynyl and branched alkynyl; and

aryl includes monocyclic and bicyclic fused 5, 6 and 7 membered aromatic rings, aryl containing 1, 2, 3 or 4 heteroatoms selected independently from O, S and N, alkylaryl for
20 example benzyl, and substituted aryl and substituted alkylaryl for example substituted benzyl.

The nature, position and number of any substituents and unsaturation present in any alkyl, alkenyl, alkynyl and aryl group may be varied.

25

Examples of suitable substituents on any of said alkyl, alkenyl, alkynyl and aryl, including alkylaryl, groups include OH, halogens, amino, CN, COOH, CO₂alkyl(C₁ to C₅), CONH₂, CONHalkyl(C₁ to C₅), O-alkyl(C₁ to C₅), SH, S-alkyl(C₁ to C₅) and NO₂, and aryl(5 to 10 ring atoms), and with respect to aryl and alkylaryl groups include alkyl (C₁ to C₅), alkenyl
30 (C₂ to C₅) and alkynyl (C₂ to C₅), wherein any of said alkyl, alkenyl, alkynyl and aryl moieties are each optionally substituted. Substituents on the said alkyl, alkenyl and alkynyl moieties, which are preferably straight chain, can be selected from the group comprising OH, halogens, amino, CN, SH and NO₂, and is preferably a halogen, more

preferably chlorine. Where the said alkyl, alkenyl or alkynyl moiety is C₂ to C₅, the substituent is preferably at the terminus position. Substituents on the said aryl moiety can be selected from the group comprising OH, halogens, amino, CN, NO₂, and C₁ to C₁₀ alkyl, which C₁ to C₁₀ alkyl moiety is optionally substituted with a member selected from

- 5 the group comprising OH, halogens, amino, CN, SH, NO₂. The said aryl moiety can comprise aryl or heteroaryl groups. Any ring heteroatoms may vary in position or number. Suitably 1, 2, 3 or 4 heteroring atoms may be present, preferably selected, independently, from O, N and S. The said aryl moiety can comprise one, or two fused, 5, 6 or 7 membered rings.

10

Preferably R¹ is selected from C₃₋₂₀alkyl, C₃₋₂₀cycloalkyl, C₂₋₂₀alkenyl, C₃₋₂₀alkynyl, C₅₋₁₄ aryl and C₁₋₁₀alkylC₅₋₁₄aryl, more preferably C₃₋₁₄alkyl, C₃₋₁₄alkenyl, C₃₋₁₄alkynyl, more preferably C₆₋₁₄alkyl, C₆₋₁₄alkenyl, C₆₋₁₄alkynyl, even more preferably C₈₋₁₀alkyl, C₈₋₁₀ alkenyl and C₈₋₁₀alkynyl.

15

Preferably R¹ is C₄₋₁₄alkyl, C₄₋₁₄alkenyl or C₄₋₁₄alkynyl, more preferably C₄₋₁₂alkyl, C₄₋₁₂alkenyl or C₄₋₁₂alkynyl, even more preferably C₆₋₁₀alkyl, C₆₋₁₀alkenyl or C₆₋₁₀alkynyl, even more preferably C₈₋₁₀alkyl, C₈₋₁₀alkenyl or C₈₋₁₀alkynyl.

- 20 Where there is a single bond between X and the ring atom to which Q is attached, R¹ is preferably C₆₋₁₂alkyl, C₆₋₁₂alkenyl or C₆₋₁₂alkynyl.

Where there is a double bond between X and the ring atom to which Q is attached, R¹ is preferably C₄₋₁₂alkyl, C₄₋₁₂alkenyl or C₄₋₁₂alkynyl.

25

Preferably R¹ is an alkyl group. Preferably R¹ is a straight chain alkyl group. Preferably R¹ is an unsubstituted alkyl group. Preferably R¹ is a saturated alkyl group.

- 30 Preferably R¹ is a C₇ to C₁₃ alkyl group. More preferably R¹ is a C₈ to C₁₂ alkyl group, even more preferably a C₉ to C₁₁ alkyl group. Particularly preferred is R¹ being a C₉ or C₁₀ alkyl group.

Where R^1 is a straight chain alkyl group, a preferred position for substitution is the terminus position.

Suitably any substituent in R^1 is non-polar, more suitably any such substituent is additionally hydrophobic. Preferred substituents on R^1 include halogen and O-alkyl(C_1 to C_5). Particularly preferred is O-alkyl with C_4 , optionally terminally substituted with a halogen, preferably chlorine.

When R^1 is a cycloalkyl group, it suitably comprises 5 to 12 ring carbon atoms arranged in one or two adjoining rings.

Preferably R^1 is selected from the group comprising nC_4H_9 , nC_6H_{13} , nC_7H_{15} and $nC_{10}H_{21}$. Preferably R^1 is $nC_{10}H_{21}$.

15 Preferably R^4 and R^8 are selected from C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, C_{3-12} cycloalkyl, C_{1-6} alkyl substituted with C_{3-10} cycloalkyl, C_{5-14} aryl and C_{1-5} alkyl C_{5-14} aryl.

Preferably R^4 and R^8 are selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_1 alkyl substituted with C_{5-6} cycloalkyl and C_1 alkyl substituted with C_{5-7} aryl.

20

Even more preferably R^4 and R^8 are selected from C_{1-6} alkyl, C_{2-4} alkenyl, C_1 alkyl substituted with C_{5-6} cycloalkyl and benzyl and substituted benzyl.

25 Preferably each of R^4 and R^8 are selected from the group comprising cyclo C_5H_9 , $CH(Et)_2$, nC_5H_{11} , 2-THF, CH_2 cyclo C_6H_{11} , 3-THF, cyclo C_6H_{11} , C_3H_7 , nC_4H_9 , $PhCH_2$, $TolCH_2$, $pMeOPhCH_2$, CH_2 cyclo C_5H_9 , Me and nC_3H_7 .

Where a single bond exists between X and the ring atom to which Q is attached particularly preferred combinations of R^1 and R^8 are, respectively, nC_7H_{15} and cyclo C_5H_9 , nC_7H_{15} and $CH(Et)_2$, $nC_{10}H_{21}$ and 3-THF, $nC_{10}H_{21}$ and cyclo C_6H_{11} , $nC_{10}H_{21}$ and C_3H_7 , $nC_{10}H_{21}$ and CH_2 cyclo C_5H_9 , nC_6H_{13} and Me, nC_6H_{13} and nC_3H_7 , and nC_6H_{13} and $PhCH_2$. A particularly preferred combination is R^1 being $nC_{10}H_{21}$ and R^8 being CH_2 cyclo C_5H_9 .

30

Where a double bond exists between X and the ring atom to which Q is attached particularly preferred combinations of R^1 and R^4 are, respectively, nC_4H_9 and $cycloC_5H_9$, nC_7H_{15} and $cycloC_5H_9$, nC_7H_5 and $CH(Et)_2$, nC_7H_{15} and nC_5H_{11} , $nC_{10}H_{21}$ and $CH(Et)_2$, ~~$nC_{10}H_{21}$ and $cycloC_6H_{11}$, $nC_{10}H_{21}$ and nC_3H_7 , $nC_{10}H_{21}$ and nC_4H_9 , $nC_{10}H_{21}$ and $PhCH_2$,~~

5 $nC_{10}H_{21}$ and $CH_2cycloC_6H_{11}$, $nC_{10}H_{21}$ and $TolCH_2$, $nC_{10}H_{21}$ and $pMeOPhCH_2$, nC_6H_{13} and Me, nC_6H_{13} and nC_4H_9 , and nC_6H_{13} and $PhCH_2$. Particularly preferred combinations are R^1 being $nC_{10}H_{21}$ with R^4 being any of nC_3H_7 , nC_4H_9 , $PhCH_2$, $CH_2cycloC_6H_{11}$, $tolCH_2$, and $pMeOPhCH_2$.

10 Suitably R^2 is selected from the group comprising H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl, C_1 to C_{10} alkylamino, C_1 to C_{10} dialkylamino, C_1 to C_{10} alkyloxy, C_6 to C_{10} aryloxy, C_1 to C_{10} alkylthiol, C_6 to C_{10} arylthiol and C_6 to C_{10} aryl.

Suitably R^3 is selected from the group comprising H, C_1 to C_{10} alkyl, C_3 to C_{10} cycloalkyl,
15 C_1 to C_{10} alkyloxy, C_6 to C_{10} aryloxy and C_6 to C_{10} aryl.

Preferably each of R^2 and R^3 is a small alkyl i.e. a C_1 to C_2 alkyl group or H. More preferably each of R^2 and R^3 is H.

20 Throughout the present specification "halogen" is taken to include any of F, Cl, Br and I.

Where not otherwise specified, alkyl is C_{1-6} alkyl, alkenyl is C_{2-6} alkenyl, alkynyl is C_{2-6} alkynyl, aryl is C_{5-14} aryl and alkylaryl is C_{1-6} alkyl C_{5-14} aryl.


25 Where R^1 , R^4 or R^8 is an aryl group, the group includes alkylaryl groups. Preferably R^1 , R^4 and R^8 are C_{5-14} aryl groups or C_{1-4} alkyl C_{5-14} aryl groups. Particularly preferred groups are benzyl and substituted benzyl such as toluene (tol) CH_2 , and $pMeOPhCH_2$. Preferred substituents include alkyl (C_{1-6}), alkoxy (C_{1-6}) and halogen (F, Cl, Br and I). The preferred substitution positions for phenyl and benzyl is para. Preferred aryl groups are C_6 .

30

According to a further aspect of the present invention there is provided a method for preparing compounds having Formula I above wherein a 5-halo nucleoside analogue is contacted with a terminal alkyne in the presence of a catalyst. alternatively 5-alkynyl

nucleoside can be cyclised in the presence of a catalyst. Suitably the catalyst is a copper catalyst.

Compounds of the present invention may be prepared by a number of methods, which may
5 for example involve a reaction scheme such as:



Thus, terminal acetylenes are coupled to 5-iodouracil under Pd catalysed conditions to give
10 intermediate 5-alkynyl compounds that may either be isolated or used in situ. These are cyclised under Cu catalysis to give bicyclic furano pyrimidines that are key synthons. these are alkylated to give mixtures of O and N alkyl products that can be readily separated.

15 The method of separation may include chromatography, precipitation, and crystallisation. The ratios of these products will vary, and need not be 1:1.

Compounds embodying the present invention can show anti-viral activity. In particular, it has surprisingly been found that compounds embodying the present invention can show
20 antiviral activity against for example cytomegalovirus.

According to a further aspect of the present invention there is provided a compound according to the present invention for use in a method of treatment, suitably in the prophylaxis or treatment of a viral infection, preferably a cytomegalovirus viral infection.

5 According to a further aspect of the present invention there is provided a method of prophylaxis or treatment of viral infection, preferably a cytomegalovirus viral infection, comprising administration to a patient in need of such treatment an effective dose of a compound according to the present invention.

10 According to a further aspect of the present invention there is provided use of a compound of the present invention in the manufacture of a medicament for use in the prophylaxis or treatment of a viral infection, particularly an infection with cytomegalovirus.

According to a further aspect of the present invention there is provided a pharmaceutical
15 composition comprising a compound of the present invention in combination with a pharmaceutically acceptable excipient.

According to a further aspect of the present invention there is provided a method of
20 preparing a pharmaceutical composition comprising the step of combining a compound of the present invention with a pharmaceutically acceptable excipient.

The compounds embodying the present invention present a number of advantages over existing agents for HCMV:

- 25
1. A novel non-nucleoside structure and possibly novel mechanism of action.
 2. Antiviral activity at non-cytotoxic concentrations.
 3. A lack of cross resistance with existing nucleoside drugs.
 4. Useful physiochemical properties such as high lipophilicity. Lead structures have calculated logP (ClogP) values of Ca. 4-6.

30

The high lipophilicity of the present compounds may lead to improved in vivo dosing, tissue distribution and pharmacokinetics. In a preliminary rodent trial a compound with structure 5 with $R^1 = C_7H_{15}$ and $R^4 =$ cyclopentyl displayed significant bioavailability and

half life following i.p. dosing. Moreover at a dose as high as 50mg/kg/day for 10 days no visible in vivo toxicity was noted, indicating a promising toxicology profile. Histology also revealed no detectable toxicity against brain, thymus, liver, lungs, kidney, breast, testis, ovum and spleen tissue.

5

The compounds embodying the present invention can be sufficiently lipophilic to warrant their formulation and use as non-p.o dosage forms including topical, transdermal and ocular formulations. The latter may be of particular value versus HCMV retinitis, common in persons co-infected with HIV. The agents would therein have significant dosing, tissue

10 localisation and toxicology advantage over current agents.

The lack of chirality in structures embodying the present invention distinguishes them from typical nucleoside antivirals with possible costs of goods and ease of synthesis advantage.

15 The medicaments employed in the present invention can be administered by oral (p.o.) or parenteral (i.p.) routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.

20 For oral administration, the compound of the invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.

Tablets for oral use may include the active ingredient mixed with pharmaceutically
 25 acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating
 30 agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

-
- 5 Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active
10 ingredient such carriers as are known in the art to be appropriate.

For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include ringer's
15 solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.

- 20 The compounds of the invention may also be presented as liposome formulations.

In general a suitable dose will be in the range of 0.1 to 300 mg per kilogram body weight of the recipient per day, preferably in the range of 1 to 25 mg per kilogram body weight per day and most preferably in the range 5 to 10 mg per kilogram body weight per day.

- 25 The desired dose is preferably presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form.


- 30 Embodiments of the present invention will now be described by way of example only.

All reagents and solvents were obtained commercially and used without further purification, unless otherwise stated. Reaction progress was monitored by thin-layer

chromatography (TLC) on DC-Alufolien 60F₂₅₄ 0.2 mm plates. Compounds were visualised by UV fluorescence (wavelength 365 nm). The reaction mixtures were evaporated in a vacuum rotary evaporator (Büchi *Rotavapor* R-114) using the vacuum of a diaphragm pump. This process is referred to below as “evaporated/removed/distilled *in vacuo*” or “under reduced pressure”. Flash column chromatography refers to the technique described by Still.ⁱ The height of the silica gel 60 (220-440 mesh) in all cases was 15 cm. All air and moisture sensitive reactions were carried out under a nitrogen atmosphere in oven-dried glassware. Reaction mixture temperatures were measured externally.

10

¹H and ¹³C NMR spectra were recorded on a Bruker Avance DPX300 spectrometer at 300 MHz and 75.5 MHz respectively, with the corresponding deuterated solvents noted. The chemical shifts are reported in parts per million relative to the residual non-deuterated solvent peak (δ_{H} CHCl₃ 7.27; δ_{H} [D₅]DMSO 2.50; and δ_{C} CHCl₃ 77.0 and δ_{C} [D₅]DMSO 39.5 central peak). *J* values are given in Hz. The DEPT and NOE techniques were used to assign different carbon atoms. Chemical shifts are reported: value (splitting pattern, number of protons, coupling constant (where applicable), and assignment). Splitting pattern is designated as follows: s, singlet; app d, apparent doublet; d, doublet; dd, double doublet; t, triplet; q, quartet; quin, quintet; sex, sextet; sept, septet; m, multiplet; and br, broad. Elemental analyses were carried out in the Microanalytical Laboratories of the School of Pharmacy, University of London.



6-Heptyl-3H-furo[2,3-d]pyrimidin-2-one (137)

To a stirred solution of 5-Iodo-uracil (3.00 g, 12.60 mmol) in dry dimethylformamide (30 ml) at room temperature and under a nitrogen atmosphere, 1-hexyne (4.20 ml, 37.80 mmol), *tetrakis*(triphenylphosphine)palladium(0) (728 mg, 0.63 mmol), copper (I) iodide (240 mg, 1.26 mmol), and diisopropylethylamine (4.4 ml, 25.20 mmol), were added.


The reaction mixture was stirred at room temperature for 19 hours, after which time TLC (chloroform/methanol 95:5) showed complete conversion of the starting material. Copper(I) iodide (240 mg, 1.26 mmol), triethylamine (20 ml) was added to the mixture which was subsequently refluxed for 8 hours. The reaction mixture was then

concentrated *in vacuo*, and the product was purified by trituration with methanol, (1.20 g, 41%).

¹H-nmr (d₆-DMSO; 300 MHz): 11.97 (1H, bs, NH), 8.15 (1H, s, H-4) 6.37 (1H, s, H-5), 2.60 (2H, t, J = 7.3 Hz, α-CH₂), 1.62 (2H, m, CH₂), 1.28 (8H, m, 4 x CH₂), 0.86 (3H, t, J = 7.2 Hz, CH₃).

¹³C-nmr unavailable due to solubility problems.

6-Butyl-3-cyclopentyl-3H-furo[2,3-d]pyrimidin-2-one (138) [Cf2158]




To a suspension of 6-Butyl-3H-furo[2,3-d]pyrimidin-2-one (136) (350 mg, 1.82 mmol) in dry DMF (20 ml) under an atmosphere of nitrogen, potassium carbonate (502 mg, 3.64 mmol) and cyclopentyl bromide (0.39 ml, 3.64 mmol) were added. The reaction mixture was stirred at 80 °C for one hour. The solvent was evaporated *in vacuo* and the residue was dissolved in dichloromethane and extracted with a saturated solution of sodium chloride. The extracts were collected, dried on magnesium sulphate and evaporated to dryness. The crude product was purified by silica column chromatography, using chloroform as eluent, followed by a mixture of chloroform/methanol (97:3). The appropriate fractions were combined and the solvent was removed *in vacuo* to yield the product, which was further purified by trituration with diethyl ether, yielding the pure product (47 mg, 10%) as a white solid. Mp: 130-131 °C.

¹H-nmr (CDCl₃; 300 MHz): 7.84 (1H, s, H-4) 6.13 (1H, s, H-5), 5.29 (1H, m, CH), 2.69 (2H, t, J = 7.2 Hz, α-CH₂), 2.33 (2H, m, cyclopentyl-CH₂), 2.01-1.67 (8H, m, cyclopentyl + CH₂), 1.45 (2H, m, CH₂), 0.99 (3H, t, J = 7.3 Hz, CH₃).

¹³C-nmr (CDCl₃; 75 MHz): 14.1 (CH₃), 22.5, 28.4, 29.3 (3 x CH₂), 24.5, 32.8 (cyclopentyl-CH₂), 59.6 (CH), 98.9 (C-5) 108.2 (C-4a), 135.6 (C-4), 156.2 (C-6), 160.3 (C-2), 171.3 (C-7a).

MS (ES+) m/e 283 (MNa⁺, 100%)

Accurate mass: C₁₅H₂₀N₂O₂Na requires 283.1422; found 283.1414.



6-Butyl-2-cyclopentyloxy-furo[2,3-*d*]pyrimidin (139)

[Cf2159]

Also isolated from the above reaction as a white solid (270 mg, 57%). Mp: 69-71 °C.

- 5 ¹H-nmr (CDCl₃; 300 MHz): 8.61 (1H, s, H-4) 6.42 (1H, s, H-5), 5.48 (1H, m, CH), 2.78 (2H, t, J = 7.2 Hz, α-CH₂), 2.06-1.67 (10H, m, cyclopentyl + β-CH₂), 1.46 (2H, m, γ-CH₂), 0.99 (3H,


t, J = 7.3 Hz, CH₃).

- 10 ¹³C-nmr (CDCl₃; 75 MHz): 14.2 (CH₃), 22.6, 28.4, 29.7 (3 x CH₂), 24.2, 33.2 (cyclopentyl-CH₂), 80.4 (CH), 99.5 (C-5) 113.9 (C-4a), 150.9 (C-4), 158.9 (C-6), 162.6 (C-2), 168.8 (C-7a).

MS (ES⁺) m/e 283 (MNa⁺, 100%)

Accurate mass: C₁₅H₂₀N₂O₂Na requires 283.1422; found 283.1428.

15 6-Heptyl-3-cyclopentyl-3*H*-furo[2,3-*d*]pyrimidin-2-one (140) [Cf2160]



This was synthesised as described for 138 above, using 350 mg of 137 (1.49 mmol) and 0.32 ml of cyclopentyl bromide (2.98 mmol). The product was collected as a white solid (88 mg, 20%). Mp: 142-143 °C.

- 20 IR (KBr): 2930.6 (aliphatic), 1677.8 (CO amide).

¹H-nmr (CDCl₃; 300 MHz): 7.80 (1H, s, H-4) 6.09 (1H, s, H-5), 5.25 (1H, m, CH), 2.64 (2H, t, J = 7.4 Hz, α-CH₂), 2.25 (2H, m, cyclopentyl-CH₂), 1.90 -1.67 (8H, m, 4 x CH₂), 1.34 (8H, m, 4 x CH₂), 0.88 (3H, t, J = 6.7 Hz, CH₃).


- 25 ¹³C-nmr (CDCl₃; 75 MHz): 14.5 (CH₃), 23.0, 27.2, 27.9, 29.3, 29.7, 32.8 (6 x CH₂), 24.5, 33.1 (cyclopentyl-CH₂), 59.7 (CH), 98.9 (C-5) 108.2 (C-4a), 135.7 (C-4), 156.2 (C-6), 160.3 (C-2), 171.6 (C-7a).

MS (ES⁺) m/e 325 (MNa⁺, 100%)

Accurate mass: C₁₈H₂₆N₂O₂Na requires 325.1892; found 325.1883

30

6-Heptyl-2-cyclopentyloxy-furo[2,3-*d*]pyrimidin (141) [Cf2161]



Also isolated from the above reaction as a white solid (230 mg, 51%). Mp: 65-67 °C.

IR (KBr): 2954.1 (aliphatic), 1619.6 (C=N).

- 35 ¹H-nmr (CDCl₃; 300 MHz): 8.60 (1H, s, H-4) 6.36 (1H, s, H-5), 5.48 (1H, m, CH), 2.77 (2H, t, J = 7.3 Hz, α-CH₂),


2.08-1.63 (10H, m, cyclopentyl + β -CH₂), 1.42-1.27 (8H, m, 4 x CH₂), 0.91 (3H, t, J = 7.2 Hz, CH₃).

¹³C-nmr (CDCl₃; 75 MHz): 14.5 (CH₃), 23.0, 27.6, 28.8, 29.4, 29.4, 32.1 (6 x CH₂), 24.2, 33.2 (cyclopentyl-CH₂), 80.4 (CH), 99.5 (C-5) 113.9 (C-4a), 150.9 (C-4), 158.9 (C-6), 162.6 (C-2), 168.8 (C-7a).

MS (ES⁺) m/e 325 (MNa⁺, 100%)

Accurate mass: C₁₈H₂₆N₂O₂Na requires 325.1892; found 325.1880

6-Butyl-3-(1-ethyl-propyl)-3H-furo[2,3-d]pyrimidin-2-one (142) [Cf2194]



This was synthesised as described for 138 above, using 300 mg of 136 (1.56 mmol) and 0.40 ml of 3-bromopentane (3.12 mmol). The product was collected as a white solid (118 mg, 29%).

IR (KBr): 2958.1 (aliphatic), 1671.9 (CO amide).

¹H-nmr (CDCl₃; 300 MHz): 7.72 (1H, s, H-4) 6.14 (1H, s, H-5), 4.94 (1H, m, CH), 2.68 (2H, t, J = 7.4 Hz, α -CH₂), 1.93-1.66 (6H, m, 3 x CH₂), 1.43 (2H, m, CH₂), 1.00-0.88 (9H, m, 3 x CH₃).


¹³C-nmr (CDCl₃; 75 MHz): 10.7, 14.1 (3 x CH₃), 22.5, 27.9, 28.4, 29.3 (5 x CH₂), 61.3 (CH), 98.9 (C-5) 108.2 (C-4a), 135.4 (C-4), 156.7 (C-6), 160.3 (C-2), 171.4 (C-7a).

MS (ES⁺) m/e 285 (MNa⁺, 100%)

20 Accurate mass: C₁₅H₂₂N₂O₂Na requires 285.1579; found 285.1586

Anal. Calcd for C₁₅H₂₂N₂O₂: C, 68.67%; H, 8.45%; N, 10.68%. Found: C, 68.38%; H, 8.62%; N, 10.89%

6-Butyl-2-(1-ethyl-propoxy)-furo[2,3-d]pyrimidine (143) [Cf2193]



Also isolated from the above reaction as a white solid (171 mg, 42%).

IR (KBr): 2938.4 (aliphatic), 1620.0 (C=N).

¹H-nmr (CDCl₃; 300 MHz): 8.60 (1H, s, H-4) 6.35 (1H, s, H-5), 5.10 (1H, m, CH), 2.77 (2H, t, J = 7.4 Hz, α -CH₂), 1.91-1.70 (6H, m, 3 x CH₂), 1.43 (2H, m, CH₂), 1.00-0.90 (9H, m, 3 x CH₃).


¹³C-nmr (CDCl₃; 75 MHz): 10.0, 14.1 (3 x CH₃), 22.6, 26.5, 28.4, 29.7 (5 x CH₂), 80.0 (CH), 99.5 (C-5) 113.9 (C-4a), 150.9 (C-4), 158.9 (C-6), 162.9 (C-2), 168.8 (C-7a).

35 MS (ES⁺) m/e 285 (MNa⁺, 100%)

Accurate mass: C₁₅H₂₂N₂O₂Na requires 285.1579; found 285.1575

Anal. Calcd for $C_{15}H_{22}N_2O_2$: C, 68.67%; H, 8.45%; N, 10.68%. Found: C, 66.97%; H, 8.58%; N, 10.78%

5 **6-Heptyl-3-(1-ethyl-propyl)-3H-furo[2,3-d]pyrimidin-2-one (144) [Cf2190]**



This was synthesised as described for 138 above, using 350 mg of 137 (1.50 mmol) and 0.40 ml of 3-bromopentane (3.00 mmol). The product was collected as a white solid (108 mg, 28%). Mp: 128-130 °C.

10 1H -nmr ($CDCl_3$; 300 MHz): 7.71 (1H, s, H-4) 6.14 (1H, s, H-5), 4.94 (1H, m, CH), 2.68 (2H, t, $J = 7.4$ Hz, α -CH₂), 1.96-1.67 (6H, m, 3 x CH₂), 1.43-1.32 (8H, m, 4 x CH₂), 0.98-0.89 (9H, m, 3 x CH₃).

15 ^{13}C -nmr ($CDCl_3$; 75 MHz): 10.7, 14.5 (3 x CH₃), 23.0, 27.2, 27.9, 28.7, 29.3 29.4, 32.1 (7 x CH₂), 61.3 (CH), 98.9 (C-5) 108.2 (C-4a), 135.4 (C-4), 156.7 (C-6), 160.3


(C-2), 171.4 (C-7a).

MS (ES+) m/e 327 (MNa^+ , 100%), 305 (MH^+) (50%)

Accurate mass: $C_{18}H_{28}N_2O_2Na$ requires 327.2048; found 327.2038

20

6-Heptyl-2-(1-ethyl-propoxy)-furo[2,3-d]pyrimidine (145) [Cf2189]



Also isolated from the above reaction as a white solid (272 mg, 70%). Mp: 70-71 °C.

25 1H -nmr ($CDCl_3$; 300 MHz): 8.48 (1H, s, H-4) 6.24 (1H, s, H-5), 5.01 (1H, m, CH), 2.65 (2H, t, $J = 7.3$ Hz, α -CH₂), 1.72-1.60 (6H, m, 3 x CH₂), 1.60-1.20 (8H, m, 4 x CH₂), 0.91-0.77 (9H, m, 3 x CH₃).

30 ^{13}C -nmr ($CDCl_3$; 75 MHz): 9.9, 14.4 (3 x CH₃), 23.0, 26.4, 27.6, 28.7, 29.3, 29.4, 32.0 (7 x CH₂), 80.0 (CH), 99.5 (C-5) 113.9 (C-4a), 150.9 (C-4), 158.8 (C-6), 162.9 (C-2), 168.8 (C-7a).


MS (ES+) m/e 327 (MNa^+ , 100%)

Accurate mass: $C_{18}H_{28}N_2O_2Na$ requires 327.2048; found 327.2053

35

6-Butyl-3-pentyl-3H-furo[2,3-d]pyrimidin-2-one (146) [Cf2195]

This was synthesised as described for 138 above, using 250 mg of 136 (1.30 mmol) and 515 mg of 1-iodopentane (2.60 mmol). The product was collected as a white solid (133 mg, 40%). Mp: 139-141 °C.



¹H-nmr (CDCl₃; 300 MHz): 7.77 (1H, s, H-4) 6.07 (1H, s, H-5), 3.96 (2H, t, J = 7.4 Hz, N-CH₂), 2.61 (2H, t, J = 7.4 Hz, α-CH₂), 1.94-1.58 (4H, m, 3 x CH₂), 1.43-1.24 (6H, m, 3 x CH₂), 0.93-0.84 (6H, m, 2 x CH₃).


¹³C-nmr (CDCl₃; 75 MHz): 14.1, 14.3 (2 x CH₃), 22.5, 22.7, 28.4, 29.0, 29.2, 29.3 (6 x CH₂), 52.6 (N-CH₂), 98.8 (C-5) 108.1 (C-4a), 139.1 (C-4), 155.8 (C-6), 160.2 (C-2), 172.3 (C-7a).

MS (ES+) m/e 285 (MNa⁺, 100%)

Accurate mass: C₁₅H₂₂N₂O₂Na requires 285.1579; found 285.1568

15 6-Butyl-2-pentyloxy-furo[2,3-d]pyrimidine (147) [Cf 2327]

Also isolated from the above reaction as a white solid (62 mg, 20%). Mp: 51-52 °C.



¹H-nmr (CDCl₃; 300 MHz): 8.49 (1H, s, H-4) 6.25 (1H, s, H-5), 4.32 (2H, t, J = 6.6 Hz, O-CH₂), 2.64 (2H, t, J = 7.3 Hz, α-CH₂), 1.85-1.66 (4H, m, 2 x CH₂), 1.43 (6H, m, 3 x CH₂), 0.92-0.73 (6H, m, 2 x CH₃).


¹³C-nmr (CDCl₃; 75 MHz): 14.1, 14.4 (2 x CH₃), 22.5, 22.8, 28.4, 28.5, 28.9, 29.6 (7 x CH₂), 68.3 (O-CH₂), 99.5 (C-5) 114.1 (C-4a), 150.9 (C-4), 159.0 (C-6), 162.8 (C-2), 168.8 (C-7a).

MS (ES+) m/e 285 (MNa⁺, 100%)

Accurate mass: C₁₅H₂₂N₂O₂Na requires 285.1579; found 285.1584

6-Heptyl-3-pentyl-3H-furo[2,3-d]pyrimidin-2-one (148) [Cf2192]

This was synthesised as described for 138 above, using 350 mg of 137 (1.50 mmol) and 594 mg of 1-iodopentane (3.00 mmol). The product was collected as a white solid (207 mg, 45%). Mp: 161-162 °C.



IR (KBr): 2922.1 (aliphatic), 1678.3 (CO amide).


¹H-nmr (CDCl₃; 300 MHz): 7.87 (1H, s, H-4) 6.18 (1H, s, H-5), 4.07 (2H, t, J = 7.4 Hz, N-CH₂), 2.71 (2H, t, J = 7.3 Hz, α-CH₂), 1.93-1.71 (4H, m, 2 x CH₂), 1.42 (12H, m, 6 x CH₂), 0.98 (6H, m, 2 x CH₃).

¹³C-nmr (CDCl₃; 75 MHz): 14.3, 14.9 (2 x CH₃), 22.7, 23.0, 27.2, 28.7, 29.1, 29.3, 29.3, 29.4, 32.1 (9 x CH₂), 52.6 (N-CH₂), 98.8 (C-5), 108.1 (C-4a), 139.1 (C-4), 155.8 (C-6), 160.3 (C-2), 172.3 (C-7a).

MS (ES+) m/e 327 (MNa⁺, 100%)

5 Accurate mass: C₁₈H₂₈N₂O₂Na requires 327.2048; found 327.2042

6-Heptyl-2-pentyloxy-furo[2,3-d]pyrimidine (149) [Cf2191]



Also isolated from the above reaction as a white solid (141 mg, 31%). Mp: 48-49 °C.

10 IR (KBr): 2933.0 (aliphatic), 1618.0 (C=N).

¹H-nmr (CDCl₃; 300 MHz): 8.50 (1H, s, H-4), 6.25 (1H, s, H-5), 4.30 (2H, t, J = 6.7 Hz, O-CH₂), 2.65 (2H, t, J = 7.4 Hz, α-CH₂), 1.80-1.60 (4H, m, 2 x CH₂), 1.44-1.19 (12H, m, 6 x CH₂),


15 0.86-0.77 (6H, m, 2 x CH₃).

¹³C-nmr (CDCl₃; 75 MHz): 14.4 (2 x CH₃), 22.8, 23.0, 27.6, 28.5, 28.7, 28.9, 29.3, 29.4, 32.0 (9 x CH₂), 68.3 (O-CH₂), 99.5 (C-5), 114.1 (C-4a), 150.8 (C-4), 159.0 (C-6), 162.8 (C-2), 172.3 (C-7a).

MS (ES+) m/e 327 (MNa⁺, 100%)

20 Accurate mass: C₁₈H₂₈N₂O₂Na requires 327.2048; found 327.2050

6-Heptyl-3-(tetrahydro-furan-2-yl)-3H-furo[2,3-d]pyrimidin-2-one (154) [Cf2196]



To a suspension of 6-heptyl-3H-furo[2,3-d]pyrimidin-2-one (137) (288 mg, 1.23 mmol) in dry DMF (10 ml) 2-tert-Butoxytetrahydrofuran (709 mg, 4.92 mmol) was added. The reaction mixture was stirred at 150°C for 10 hours. The solvent was evaporated *in vacuo* and the residue was dissolved in dichloromethane and purified by silica column chromatography, using chloroform as eluent, followed by a mixture of chloroform/methanol (98:2). The appropriate fractions were combined and the solvent was removed *in*

vacuo to yield the product, which was further purified by trituration with diethyl ether, yielding the pure product (150 mg, 40%) as a white solid.

35 IR (KBr): 2927.1 (aliphatic), 1671.9 (CO amide), 1084.0 (C-O).

^1H -nmr (CDCl_3 ; 300 MHz): 7.93 (1H, s, H-4) 6.09 (2H, m, H-5 and H-1'), 4.26 and 4.04 (2H, m, H-5'), 2.60 (2H, t, $J = 7.4$ Hz, $\alpha\text{-CH}_2$), 2.56 (2H, m, H-2'a), 2.18 and 2.00 (2H, m, H-3') 1.99 (2H, m, H-2'b), 1.59 (2H, m, CH_2), 1.30-1.23 (8H, m, $4 \times \text{CH}_2$), 0.83 (3H, t, $J = 6.7$ Hz, CH_3).


5 ^{13}C -nmr (CDCl_3 ; 75 MHz): 14.5 (CH_3), 23.0, 23.7, 27.2, 28.7, 29.3, 29.4, 32.1, 33.8 ($8 \times \text{CH}_2$), 71.1 (C-5'), 90.2 (C-1'), 99.1 (C-5), 107.6 (C-4a), 134.2 (C-4), 155.2 (C-6), 160.2 (C-2), 171.3 (C-7a).

MS (ES+) m/e 327 (MNa^+ , 100%)


Accurate mass: $\text{C}_{17}\text{H}_{24}\text{N}_2\text{O}_3\text{Na}$ requires 327.1685; found 327.1678

10 Anal. Calcd for $\text{C}_{17}\text{H}_{24}\text{N}_2\text{O}_3$: C, 67.08%; H, 7.95%; N, 9.20%. Found: C, 67.01%; H, 8.14%; N, 9.26%


6-Decyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one 26



15 To a dry DMF (50 mL) solution of 5-iodouracil 23 (5.00 g, 21 mmol), tetrakis(triphenylphosphine)palladium(0) (1.00 g, 0.87 mmol, 0.04 equiv.) and copper iodide (0.80 g, 4.2 mmol, 0.2 equiv.) under a nitrogen atmosphere was added dry DIPEA (7.3 mL, 5.42 g, 42 mmol, 2 equiv.) and 1-dodecyne 24 (13.5 mL, 10.48 g, 63 mmol, 3 equiv.) *via* syringe with stirring. The initially opaque yellow solution proceeded to change
20 colour on stirring at room temperature to a clear dark yellow solution, and eventually an opaque dark green suspension formed after a couple of hours. The suspension was allowed to react at RT with stirring for 18 h. TLC analysis of the resulting mixture indicated that most of the starting material had reacted, and the presence of a blue fluorescent spot was clearly observed. Dry triethylamine (25 mL) and a further addition of copper iodide (0.80
25 g) was then made to the suspension, and the resultant reaction mixture heated to 80 °C for 6 h with stirring under N_2 . The suspension was allowed to cool to RT overnight with stirring. The resultant precipitate was collected by suction filtration, and washed consecutively with methanol and DCM. The collected solid was triturated in hot methanol to yield *the title compound 26* as a white insoluble solid of weight 3.79 g (65 % from 23).

6-Decyl-2-propoxy-furo[2,3-*d*]pyrimidine Cf2303

5 26 (0.30 g, 1.086 mmol), potassium carbonate (0.30 g, 2.17 mmol, 2 equiv) and 1-iodopropane (30, 0.22 mL, 2.17 mmol, 2 equiv.) were suspended in dry DMF (5 mL) under N₂, and the reaction mixture heated to 100 °C with stirring overnight. The solvent was then removed *in vacuo* at 80 °C, and the crude mixture purified by flash chromatography in a 0-5 % methanol/DCM eluent gradient to yield 31 (102 mg, 29 %), *the title compound*, as
 10 a white solid. ¹H NMR (CDCl₃) δ 8.48 (s, 1H, 4-H), 6.49 (s, 1H, 5-H), 4.44 (t, *J* = 6.7 Hz, 2H, O-CH₂-), 2.81 (t, *J* = 7.6 Hz, 2H, 1'-CH₂), 1.95 (app sex, *J* = 7.1 Hz, 2H, CH₂), 1.82 (m, *J* = 6.6 Hz, 2H, CH₂), 1.43 (m, 14H, CH₂), 1.15 (t, *J* = 7.4 Hz, 3H, O-CH₂CH₃), 0.97 (t, *J* = 7.0 Hz, 3H, -CH₂CH₃); ¹³C NMR (CDCl₃) δ 168.9 (7a-C), 162.9 (2-C), 159.1 (6-C), 150.9 (4-CH), 114.2 (4a-C), 99.5 (5-CH), 69.9 (O-CH₂), 32.3 (1'-CH₂), 30.0 (CH₂),
 15 29.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.5 (CH₂), 28.8 (CH₂), 27.6 (CH₂), 23.1 (CH₂), 22.6 (CH₂), 14.5 (O-CH₂CH₃), 10.9 (-CH₂CH₃).

6-Decyl-3-propyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2304


20

Also isolated from the mix was 191 mg of *the title compound* 32 (55 % yield) as a white solid. ¹H NMR (CDCl₃) δ 7.74(s, 1H, 4-H), 6.13(s, 1H, 5-H), 4.01 (t, *J* = 7.3 Hz, 2H, N-CH₂-), 2.70 (t, *J* = 7.7 Hz, 2H, 1'-CH₂), 1.89 (app sex, *J* = 7.4 Hz, 2H, CH₂), 1.89
 25 (m, *J* = 7.4 Hz, 2H, CH₂), 1.70 (m, *J* = 7.4 Hz, 2H, CH₂), 1.38 (m, 14H, CH₂), 1.04 (t, *J* =

7.4 Hz, 3H, N-CH₂CH₃), 0.96 (t, $J = 7.0$ Hz, 3H, -CH₂CH₃); ¹³C NMR (CDCl₃) δ 169.9 (7a-C), 160.4 (2-C), 156.1 (6-C), 138.9 (4-CH), 108.6 (4a-C), 98.6 (5-CH), 54.2 (N-CH₂), 32.3 (1'-CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.5 (CH₂), 28.7 (CH₂), 27.2 (CH₂), 23.1 (CH₂), 22.8 (CH₂), 14.5 (O-CH₂CH₃), 11.5 (-CH₂CH₃).

5

2-Butoxy-6-decyl-furo[2,3-*d*]pyrimidine Cf2305




10 26 (0.30 g, 1.086 mmol), potassium carbonate (0.30 g, 2.17 mmol, 2 equiv) and 1-iodobutane 33 (0.25 mL, 2.17 mmol, 2 equiv.) were suspended in dry DMF (5 mL) under N₂, and the reaction mixture heated to 100 °C with stirring overnight. The solvent was then removed *in vacuo* at 80 °C, and the crude mixture purified by flash chromatography in a 0-5 % methanol/DCM eluent gradient to yield 34 (114 mg, 32 %) as white solid. ¹H

15 NMR (CDCl₃) δ 8.61 (s, 1H, 4-H), 6.36 (s, 1H, 5-H), 4.36 (t, $J = 6.7$ Hz, 2H, O-CH₂-), 2.75 (t, $J = 7.6$ Hz, 2H, 1'-CH₂), 1.90-1.74 (m, 4H, CH₂), 1.54 (m, 2H, CH₂), 1.29 (m, 14H, CH₂), 1.00 (t, $J = 6.8$ Hz, 3H, O-CH₂CH₃), 0.91 (t, $J = 7.0$ Hz, 3H, -CH₂CH₃); ¹³C


20 NMR (CDCl₃) δ 168.9 (7a-C), 162.9 (2-C), 159.1 (6-C), 150.9 (4-CH), 113.9 (4a-C), 99.5 (5-CH), 68.1 (O-CH₂), 32.3 (1'-CH₂), 31.3 (CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.5 (CH₂), 28.8 (CH₂), 27.6 (CH₂), 23.1 (CH₂), 19.6 (CH₂), 14.5 (O-CH₂CH₃), 14.2 (-CH₂CH₃).

3-Butyl-6-decyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2306



Also isolated from the mixture was *the title compound 35* (205 mg, 57 % yield) as a white solid. ^1H NMR (CDCl_3) δ 7.76 (s, 1H, 4-H), 6.04 (s, 1H, 5-H), 3.93 (t, $J = 7.4$ Hz, 2H, N- CH_2 -), 2.56 (t, $J = 7.4$ Hz, 2H, 1'- CH_2), 1.71 (m, 2H, CH_2), 1.60 (m, 2H, CH_2), 1.36-1.18 (m, 16H, CH_2), 0.88 (t, $J = 7.2$ Hz, 3H, N- $\text{CH}_2\text{-CH}_3$), 0.80 (t, $J = 6.5$ Hz, 3H, - CH_2CH_3); ^{13}C NMR (CDCl_3) δ 172.3 (7a-C), 160.3 (2-C), 155.9 (6-C), 139.2 (4-CH), 108.2 (4a-C), 98.8 (5-CH), 52.4 (N- CH_2 -), 32.3 (1'- CH_2), 31.6 (CH_2), 30.0 (CH_2), 29.9 (CH_2), 29.7 (CH_2), 29.5 (CH_2), 29.4 (CH_2), 28.7 (CH_2), 27.2 (CH_2), 23.1 (CH_2), 20.2 (10 (CH_2), 14.5 (O- CH_2CH_3), 14.1 (- CH_2CH_3).

6-Decyl-2-pentyloxy-2,3-dihydrofuro[2,3-*d*]pyrimidine Cf2247




15

6-Decyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one **26** (200 mg, 0.72 mmol), potassium carbonate (199 mg, 1.44 mmol, 2 equiv.) and 1-iodopentane **36** (0.2 mL, 2 equiv.) were suspended in dry DMF (8 mL) under N_2 , and the suspension heated to 120 °C with stirring for 4 h. The solvent was removed *in vacuo* at 80 °C, with subsequent additions and removals of toluene (2 mL) to eliminate DMF traces. The crude residue was purified by flash column chromatography to yield **37** (88 mg, 35 %) as a cream solid. ^1H NMR (CDCl_3) δ 8.57 (s, 1H, 4-H), 6.33 (s, 1H, 5-H), 4.38 (t, 2H, $J = 6.7$ Hz, 1'- CH_2), 2.73 (t, 2H, $J = 7.4$ Hz, $\alpha\text{-CH}_2$), 1.84 (qt, 2H, $J = 6.8$ Hz, CH_2), 1.74 (m, 2H, CH_2), 1.50-1.26 (m, 20 (CH_2), 1.50-1.26 (m,

18H, 9 x CH₂); 0.94-0.85 (m, 6H, 2 x CH₃); ¹³C NMR (CDCl₃) δ 168.9 (7a-C), 162.9 (2-C), 159.1 (6-C), 150.9 (4a-C), 99.5 (5-CH), 68.4 (1'-CH₂), 32.3 (CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.5 (CH₂), 28.9 (CH₂), 28.8 (CH₂), 28.7 (CH₂), 28.5 (CH₂), 27.6 (CH₂), 23.1 (CH₂), 22.9 (CH₂), 14.5 (CH₃), 14.4 (CH₃). Elemental analysis calcd for


5 C₂₁H₃₄N₂O₂ (346.5): C 72.79, N 8.08, H 9.89; found C 73.68, N 10.03, H 8.06.

2-Cyclopentyloxy-6-decyl-2,3-dihydrofuro[2,3-d]pyrimidine Cf2250




10 26 (1.00 g, 3.62 mmol), potassium carbonate (1.00 g, 7.24 mmol, 2 equiv.) and cyclopentyl bromide 39 (0.23 mL, 2.17 mmol, 2 equiv.) were suspended in dry DMF (15 mL) under N₂, and the mixture stirred at RT for 6 h. The grey/green suspension was then heated to 120 °C for 5 h, then allowed to cool with stirring overnight. The solvent was removed *in vacuo* at 80 °C. The crude residue was purified by flash column
15 chromatography in 0-1% MeOH/DCM eluent gradient to yield 40 as a white solid (0.87 g, 70 % yield). ¹H NMR (CDCl₃) δ 8.48 (b, 1H, 4-H), 6.23 (s, 1H, 5-H), 5.36 (m, 1H, 1'-H), 2.65 (t, 2H, *J* = 7.5 Hz, α-CH₂), 1.93-1.52 (m, 10H, 5 x CH₂), 1.25-1.17 (m, 14H, 7 x CH₂), 0.78 (t, 3H, *J* = 6.5 Hz, CH₃); ¹³C NMR (CDCl₃) δ = 168.8 (7a-C), 162.5 (2-C), 158.9 (6-C), 150.9 (4-CH), 113.9 (4a-C), 99.5 (5-CH), 80.3 (1'-CH), 33.1 (2 x CH₂), 32.3
20 (CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.5 (CH₂), 28.7 (CH₂), 27.6 (2 x CH₂), 24.2 (CH₂), 23.1 (CH₂), 14.5 (CH₃). Elemental analysis calcd for C₂₁H₃₂N₂O₂ (344.5): C 73.22, N 8.13, H 9.36; found C 73.85, N 8.61, H 9.84.

3-Cyclopentyl-6-decyl-2,3-dihydrofuro[2,3-*d*]pyridimin-2-one Cf2251



5 Also isolated from the above reaction was *the title compound 41* (0.18 g, 14 %) as a yellow solid. ^1H NMR (CDCl_3) δ 7.79 (s, 1H, 4-H), 6.05 (s, 1H, 5-H), 5.16 (m, 1H, 1'-H), 2.56 (t, 2H, $J = 7.5$ Hz, $\alpha\text{-CH}_2$), 2.16 (m, 2H, CH_2), 1.82-1.55 (m, 8H, 4 x CH_2), 1.25-1.19 (m, 14H, 7 x CH_2), 0.80 (t, 3H, $J = 6.4$ Hz, CH_3); ^{13}C NMR (CDCl_3) δ 171.6 (7a-C), 160.3 (6-C), 156.2 (2-C), 135.8 (4-CH), 108.3 (4a-C), 99.0 (5-CH), 59.7 (1'- CH_2), 32.8 (2 x CH_2), 32.3 (CH_2), 30.0 (CH_2), 29.7 (CH_2), 29.4 (CH_2), 28.7 (CH_2), 27.2 (2 x CH_2), 24.5 (CH_2), 23.1 (CH_2), 14.5 (CH_3). Elemental analysis calcd for $\text{C}_{21}\text{H}_{32}\text{N}_2\text{O}_2$ (344.5): C 73.22, N 8.13, H 9.36; found C 72.83, N 8.18, H 9.84.

2-(1'-Ethyl-propyloxy)-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidine Cf2252




15

26 (0.50 g, 1.81 mmol), potassium carbonate (0.50 g, 3.62 mmol, 2 equiv) and 3-bromopentane 42 (0.45 mL, 3.62 mmol, 2 equiv.) were suspended in dry DMF (15 mL) under N_2 , and the reaction mixture heated to 120 $^\circ\text{C}$ with stirring for 150 min. The dark suspension was allowed to cool to RT over 2 h, and then the solvent was removed under reduced pressure at 80 $^\circ\text{C}$. The residue was then subjected to flash column chromatography purification in a 0-5 % MeOH/DCM eluent gradient to yield 43 as a yellow oil of weight 0.27 g (43 % yield). ^1H NMR (CDCl_3) δ = 8.44 (s, 1H, 4-H), 6.20 (s,

1H, 5-H), 4.96 (qt, 1H, $J = 6.0$ Hz, 1'-H), 2.60 (t, 2H, $J = 7.5$ Hz, α -CH₂), 1.68-1.55 (m, 6H, 3 x CH₂), 1.24-1.13 (m, 12H, 6 x CH₂), 0.84 (t, 6H, $J = 7.4$ Hz, 2 x CH₃), 0.74 (t, 3H, $J = 6.9$ Hz, CH₃); ¹³C NMR (CDCl₃) $\delta = 168.8$ (7a-C), 162.9 (6-C), 158.7 (2-C), 150.9 (4-CH), 113.9 (4a-C), 99.5 (5-CH), 79.9 (1'-CH), 32.2 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.4 (CH₂), 28.7 (CH₂), 27.6 (CH₂), 26.7 (2 x CH₂), 26.4 (CH₂), 23.0 (CH₂), 14.4 (CH₃), 9.9 (2 x CH₃). Elemental analysis calcd for C₂₁H₃₄N₂O₂ (346.5): C 72.79, N 8.08, H 9.89; found C 73.12, N 8.56, H 9.93.


3-(1'-Ethyl-propyl)-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one Cf2253



10


Also isolated from the above reaction was *the title compound 44* as a white solid (0.168 g, 27 %). ¹H NMR (CDCl₃) $\delta = 7.72$ (s, 1H, 4-H), 6.15 (s, 1H, 5-H), 4.94 (b, 1H, 1'-H), 2.67 (t, 2H, $J = 7.4$ Hz, α -CH₂), 1.87 (m, 2H, CH₂), 1.71 (m, 4H, 2 x CH₂), 1.36-1.23 (m, 14H, 7 x CH₂), 0.91 (t, 9H, $J = 6.8$ Hz, 3 x CH₃); ¹³C NMR (CDCl₃) $\delta = 171.2$ (7a-C), 160.4 (6-C), 156.7 (2-C), 135.5 (4-CH), 108.3 (4a-C), 98.9 (5-CH), 32.3 (CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (2 x CH₂), 29.5 (CH₂), 28.7 (CH₂), 28.0 (CH₂), 27.2 (CH₂), 23.1 (CH₂), 14.5 (CH₃), 10.8 (2 x CH₃). Elemental analysis calcd for C₂₁H₃₄N₂O₂ (346.5): C 72.79, N 8.08, H 9.89; found C 72.65, N 8.16, H 10.08.

20 2-Cyclohexyloxy-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidine Cf2294




26 (300 mg, 1.086 mmol) and potassium carbonate (299 mg, 2.17 mmol, 2 equiv.) were suspended in dry DMF (10 mL) and cyclohexyl bromide 45 (0.54 mL, 2.17 mmol, 2 equiv.) added *via* syringe under N₂. The suspension was heated with stirring to 100 °C overnight. The solvent was removed *in vacuo* at 80 °C. The residue was suspended in DCM and washed with water. The organic layer was dried over MgSO₄, the solvent distilled *in vacuo* and the resultant residue purified by flash column chromatography in a 0-2 % MeOH/DCM eluent gradient to yield 46 as a clear colourless waxy solid (78 mg, 20 % yield). ¹H NMR (CDCl₃) δ = 8.68 (s, 1H, 4-H), 6.43 (s, 1H, 5-H), 5.16 (m, 1H, 1'-H), 2.85 (t, 2H, *J* = 7.4 Hz, α-CH₂), 2.19 (m, 2H, CH₂), 1.94 (m, 2H, CH₂), 1.84 (m, 2H, CH₂), 1.72 (m, 2H, CH₂), 1.58-1.32 (m, 18H, 9 x CH₂), 0.99 (t, 3H, *J* = 6.4 Hz, CH₃); ¹³C NMR (CDCl₃) δ 168.9 (7a-C), 162.3 (2-C), 158.9 (6-C), 151.0 (4-CH), 114.0 (4a-C), 99.6 (5-CH), 75.8 (1'-CH), 32.3 (CH₂), 32.0 (CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (2 x CH₂), 29.5 (CH₂), 28.8 (CH₂), 27.6 (CH₂), 26.0 (CH₂), 24.3 (2 x CH₂), 23.1 (CH₂), 14.6 (CH₃).

15 **3-Cyclohexyl-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one Cf2295**




Also isolated from the above reaction was *the title compound* 47 (23 mg, 6 %) as a white solid. ¹H NMR (CDCl₃) 7.86 (s, 1H, 4-H), 6.13 (s, 1H, 5-H), 4.90 (m, 1H, 1'-H), 2.68 (t, 2H, *J* = 7.4 Hz, α-CH₂), 2.09-1.30 (m, 26H, 13 x CH₂), 0.93 (t, 3H, *J* = 6.2 Hz, CH₃); ¹³C NMR (CDCl₃) δ 171.5 (7a-C), 160.3 (2-C), 155.8 (6-H), 135.6 (4-CH), 108.1 (4a-C), 98.9 (5-CH), 57.1 (1'-CH), 33.3 (CH₂), 32.3 (CH₂), 32.0 (2 x CH₂), 29.7 (2 x CH₂), 26.2 (CH₂), 25.8 (CH₂), 24.3 (CH₂), 23.1 (CH₂), 14.6 (CH₃).

25 **6-Decyl-3-(tetrahydro-furan-2-ylmethyl)-3*H*-furo[2,3-*d*]pyrimidin-2-one 72 Cf2309**



The title compound **72** (157 mg, 42 %) was also isolated from the reaction mixture as a white solid. ^1H NMR (CDCl_3) δ 7.95 (s, 1H, 4-H), 6.13 (s, 1H, 5-H), 4.55 (dd, $J = 2.3$, 13.6 Hz, 1H, N- CH_2 -THF), 4.29 (m, 1H, N- CH_2 -THF), 3.93-3.72 (m, 3H, THF-CH), 2.68 (t, $J = 7.4$ Hz, 2H, 1'- CH_2), 2.26-2.15 (m, 1H, THF-CH), 2.00-1.90 (m, 2H, CH_2), 1.71-1.63 (m, 3H, THF-CH), 1.37-1.31 (m, 14H, CH_2), 0.93 (t, $J = 6.4$ Hz, 3H, CH_3); ^{13}C NMR (CDCl_3) δ 172.4 (7a-C), 160.2 (2-C), 156.1 (6-C), 140.5 (4-CH), 107.9 (4a-C), 98.9 (5-CH), 77.3 (THF-C), 68.6 (THF-C), 54.9 (N-1'- CH_2 -THF), 32.3 (CH_2), 30.0 (CH_2), 29.9 (CH_2), 29.8 (CH_2), 29.7 (CH_2), 29.5 (CH_2), 29.2 (CH_2), 28.7 (CH_2), 27.2 (CH_2), 26.2 (CH_2), 23.1 (CH_2), 14.6 ($-\text{CH}_2\text{CH}_3$).

2-Cyclohexylmethoxy-6-decyl-furo[2,3-*d*]pyrimidine Cf2274




15

26 (0.30 g, 1.086 mmol) and potassium carbonate (0.30 g, 2.17 mmol, 2 equiv) were suspended in dry DMF (10 mL) under N_2 , and (bromomethyl)cyclohexane **48** (0.30 mL, 2.17 mmol, 2 equiv.) added *via* syringe to the resultant stirred suspension. The suspension was then heated to 120 $^\circ\text{C}$ with stirring for 3 h, then allowed to cool with stirring overnight. The solvent was then removed *in vacuo* at 80 $^\circ\text{C}$, and the crude mixture purified by flash chromatography in a 0-2% methanol/DCM eluent gradient to yield **49** (189 mg, 47 %) as white solid. ^1H NMR (CDCl_3) δ 8.63 (s, 1H, 4-H), 6.67 (s, 1H, 5-H), 4.35 (d, $J = 6.2$ Hz, 2H, O- CH_2 -CyHx), 2.79 (t, $J = 7.4$ Hz, 2H, 1'- CH_2), 1.97-1.90 (m, 3H,

CyHx-CH), 1.78 (m, 6H, CyHx-CH), 1.38-1.31 (m, 16H, CH₂), 1.19-1.08 (m, 2H, CyHx-CH), 0.91 (t, $J = 6.4$ Hz, 3H, -CH₂CH₃); ¹³C NMR (CDCl₃) δ 168.9 (7a-C), 163.0 (2-C), 159.1 (6-C), 150.9 (4-CH), 114.2 (4a-C), 99.5 (5-CH), 73.6 (O-CH₂-CyHx), 37.7 (CyHx-C), 32.3 (1'-CH₂), 30.2 (CyHx-C), 30.0 (2 X CH₂), 29.8 (CH₂), 29.7 (CH₂), 29.5 (CH₂), 28.8 (CH₂), 27.6 (CH₂), 26.9 (CH₂), 26.2 (2 X CH₂), 23.1 (CH₂), 14.6 (-CH₂CH₃).


3-Cyclohexylmethyl-6-decyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2275



10


Also isolated from the mix as a white solid in a yield of 33 % (129 mg) was *the title compound 50*. ¹H NMR (CDCl₃) δ 7.72 (s, 1H, 4-H), 6.12 (s, 1H, 5-H), 3.64 (d, $J = 7.3$ Hz, 2H, N-CH₂-CyHx), 2.66 (t, $J = 7.5$ Hz, 2H, 1'-CH₂), 2.04-1.95 (m, 1H, CyHx-CH), 1.94-1.68 (m, 6H, CyHx-CH), 1.35-1.29 (m, 16H, CH₂), 1.23 (m, 2H, CyHx-CH), 1.02 (m, 2H, CyHx-CH), 0.90 (t, $J = 6.4$ Hz, 3H, -CH₂CH₃); ¹³C NMR (CDCl₃) δ 172.3 (7a-C), 160.3 (2-C), 156.0 (6-C), 139.7 (4-CH), 107.7 (4a-C), 98.7 (5-CH), 58.8 (N-CH₂-CyHx), 36.9 (CyHx-C), 32.3 (1'-CH₂), 30.9 (CyHx-C), 30.0 (CH₂), 29.9 (CH₂), 29.8 (CH₂), 29.6 (CH₂), 29.5 (CH₂), 28.7 (CH₂), 27.2 (CH₂), 26.6 (CH₂), 26.0 (2 X CH₂), 23.1 (CH₂), 14.6 (-CH₂CH₃).

2-Benzyloxy-6-decyl-furo[2,3-*d*]pyrimidine Cf2307




26 (0.30 g, 1.086 mmol), potassium carbonate (0.30 g, 2.17 mmol, 2 equiv) and benzyl chloride (51, 0.25 mL, 2.17 mmol, 2 equiv.) were suspended in dry DMF (5 mL) under N₂, and the reaction mixture heated to 100 °C with stirring overnight. The solvent was then removed *in vacuo* at 80 °C, and the crude mixture purified by flash chromatography in a 0-5 % methanol/DCM eluent gradient to yield 52 (54 mg, 14 %) as white solid. ¹H NMR (CDCl₃) δ 8.66 (s, 1H, 4-H), 7.57 (d, *J* = 6.7 Hz, 2H, Ar-CH), 7.36 (m, 3H, Ar-CH), 6.40 (s, 1H, 5-H), 5.54 (s, 2H, O-CH₂-Ph), 2.78 (t, *J* = 7.2 Hz, 2H, 1'-CH₂), 1.79 (m, 2H, CH₂), 1.32 (m, 14H, CH₂), 0.92 (m, 3H, -CH₂CH₃); ¹³C NMR (CDCl₃) δ 168.8 (7a-C), 162.5 (2-C), 159.4 (6-C), 150.9 (4-CH), 137.0 (Ar-C), 128.8 (Ar-C), 128.4 (Ar-C), 128.3 (Ar-C), 113.9 (4a-C), 99.6 (5-CH), 69.7 (O-CH₂-Ph), 32.3 (1'-CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (2 X CH₂), 29.5 (CH₂), 28.8 (CH₂), 27.6 (CH₂), 23.1 (CH₂), 14.6 (-CH₂CH₃).

15 **3-Benzyl-6-decyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2308**



Also isolated from the crude residue was the title compound 53 (258 mg, 65 %) as white solid. ¹H NMR (CDCl₃) δ 7.74 (s, 1H, 4-H), 7.42 (m, 5H, Ar-CH), 6.07 (s, 1H, 5-H), 5.26 (s, 2H, N-CH₂-Ph), 2.67 (t, *J* = 7.3 Hz, 2H, 1'-CH₂), 1.83 (m, 2H, CH₂), 1.66 (m, 14H, CH₂), 0.93 (t, *J* = 6.9 Hz, 3H, -CH₂CH₃); ¹³C NMR (CDCl₃) δ 172.3 (7a-C), 160.8 (2-C), 156.1 (6-C), 138.3 (4-CH), 135.9 (Ar-C), 129.6 (Ar-C), 129.1 (Ar-C), 129.0 (Ar-C), 108.6 (4a-C), 98.8 (5-CH), 54.4 (N-CH₂-Ph), 32.3 (1'-CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.4 (CH₂), 28.7 (CH₂), 27.2 (CH₂), 23.1 (CH₂), 14.5 (-CH₂CH₃).

6-Decyl-3-(tetrahydro-furan-2'-yl)-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one
Cf2249




5

26 (0.30 g, 0.19 mmol) and a catalytic amount of DMAP were suspended in dry DMF (8 mL) under an atmosphere of N₂, and 2-*tert*-butoxytetrahydrofuran 54 (0.34 mL, 0.31 g, 2.17 mmol, 2 equiv.) added *via* syringe with stirring. The resultant green
 10 suspension was heated to 150 °C for 5 h with stirring, then the solvent was removed under reduced pressure at 80 °C. The residue was purified *via* flash column chromatography in DCM to yield 90 mg (24 %) of *the title compound 55* as a pale yellow compound. ¹H NMR (CDCl₃) δ 7.95 (s, 1H, 4-H), 6.10 (m, 2H, 5-H and 2'-H), 4.29 (m, 1H, 5'-H), 4.06 (m, 1H, 5'-H), 2.63 (t, 2H, *J* = 7.5 Hz, α-CH₂), 2.56 (m, 1H, THF-CH), 2.17 (m, 1H, THF-
 15 CH), 2.01 (m, 1H, THF-CH), 1.83 (m, 1H, THF-CH), 1.66 (m, 2H, CH₂), 1.30-1.1.9 (m, 14H, 7 x CH₂), 0.86 (t, 3H, *J* = 6.3 Hz, CH₃); ¹³C NMR (CDCl₃) δ 171.9 (7a-C), 160.0 (6-C), 155.2 (2-C), 134.2 (4-CH), 107.6 (4a-C), 99.1 (5-CH), 90.2 (2'-CH), 71.1 (5'-CH₂), 33.8 (CH₂), 32.3 (CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (2 x CH₂), 29.5 (CH₂), 28.7 (CH₂), 27.2 (CH₂), 23.7 (CH₂), 23.1 (CH₂), 14.6 (CH₃).


20

Methanesulfonic acid tetrahydro-furan-3-yl ester 64



3-Hydroxytetrahydrofuran **57** (0.50 g, 0.46 mL, 5.5 mmol) and triethylamine (1 mL, 7 mmol, 1.3 equiv.) were dissolved in dry DCM (5 mL) and the solution cooled to 0 °C with stirring. Methanesulfonyl chloride **63** (0.55 mL, 7 mmol, 1.3 equiv.) was added slowly *via* syringe to the chilled solution. The solution was allowed to warm to RT, and the resultant suspension stirred at RT for 24 h. Dry DCM (20 mL) was then added to the suspension to re-form a solution. The solution was allowed to stir at RT for a further 36 h. The solvent was removed *in vacuo* and the residue dissolved in water. The aqueous solution was extracted with DCM. The DCM extracts were then washed with brine, and the brine washings extracted with fresh DCM. The combined organic layers were then dried over MgSO₄. The solvent was removed under reduced pressure to yield **64** as a yellow viscous liquid (0.80 g, 96 %), which was used without further purification. ¹H NMR (CDCl₃) δ 5.20 (m, 1H, 1'-CH), 3.94-3.74 (m, 4H, THF-CH), 2.96 (s, 3H, CH₃), 2.18-2.11 (m, 2H, THF-CH); ¹³C NMR (CDCl₃): 81.38 (1'-CH), 73.4 (2'-CH₂), 67.1 (4'-CH₂), 38.8 (CH₃), 33.7 (3'-CH₂).

6-Decyl-2-(tetrahydro-furan-3-yloxy)-furo[2,3-*d*]pyrimidine **58**




20

26 (0.182 g, 0.66 mmol), potassium carbonate (0.182 g, 1.33 mmol, 2 equiv) and methanesulfonic acid tetrahydro-furan-3-yl ester **64** (0.105 g, 0.63 mmol, 0.95 equiv) were suspended in dry DMF (5 mL) under N₂, and the reaction mixture heated to 80 °C with stirring for 8 h. The solvent was then removed *in vacuo* at 80 °C, and the resultant residue purified by flash chromatography in a 0-5 % methanol/DCM eluent gradient to yield **58** (140 mg, 62 %) as white solid. ¹H NMR (CDCl₃) δ 8.64 (s, 1H, 4-H), 6.40 (s, 1H, 5-H), 5.64-5.59 (m, 1H, O-1'-THF), 4.07-3.96 (m, 4H, THF-CH), 2.80 (t, *J* = 7.5 Hz, 2H, 1'-CH₂), 1.79 (quin, *J* = 7.6 Hz, 2H, CH₂), 1.39-1.31 (m, 14H, CH₂), 0.93 (t, *J* = 6.5 Hz, 3H, -

CH_2CH_3); ^{13}C NMR (CDCl_3) δ 168.6 (7a-C), 163.0 (2-C), 159.5 (6-C), 151.0 (4-CH), 114.6 (4a-C), 99.6 (5-CH), 78.2 (1'-THF-C), 78.2 (THF-C), 73.8 (THF-C), 67.7 (1'-THF-C), 33.5 (1'- CH_2), 32.3 (CH_2), 30.0 (CH_2), 29.9 (CH_2), 29.8 (CH_2), 29.7 (CH_2), 29.5 (CH_2), 28.8 (CH_2), 27.6 (CH_2), 23.1 (CH_2), 14.6 ($-\text{CH}_2\text{CH}_3$).

5


6-Decyl-3-(tetrahydro-furan-3-yl)-3H-furo[2,3-*d*]pyrimidin-2-one Cf2276



10 Also isolated from the residue was *the title compound 59* as a white solid (22 mg, 10 %). ^1H NMR (CDCl_3) δ 8.00 (s, 1H, 4-H), 6.12 (s, 1H, 5-H), 5.68 (m, 1H, N-1'-THF), 4.23-4.09 (m, 2H, THF-CH), 3.97-3.86 (m, 2H, THF-CH), 2.68 (m, 2H, 1'- CH_2), 1.72 (m, 2H, CH_2), 1.36-1.30 (m, 16H, CH_2), 0.91 (t, $J = 6.3$ Hz, 3H, $-\text{CH}_2\text{CH}_3$); ^{13}C NMR (CDCl_3) δ 171.8 (7a-C), 160.7 (2-C), 156.0 (6-C), 136.0 (4-CH), 109.1 (4a-C), 99.1 (5-CH), 73.4 (1'-THF-C), 78.2 (THF-C), 67.6 (THF-C), 58.1 (1'-THF-C), 34.2 (1'- CH_2), 32.3 (CH_2), 30.0 (CH_2), 29.9 (CH_2), 29.7 (CH_2), 29.6 (CH_2), 29.4 (CH_2), 28.7 (CH_2), 27.2 (CH_2), 23.1 (CH_2), 14.5 ($-\text{CH}_2\text{CH}_3$).

20

Methanesulfonic acid tetrahydro-furan-3-yl methyl ester 66




Tetrahydro-3-furan methanol 65 (0.50 g, 4.9 mmol) was dissolved in dry DCM (30 mL) and triethylamine (1.06 mL, 8.8 mmol, 1.8 equiv) was added to the solution *via*

syringe under N₂ with stirring. The solution was cooled to 0 °C and methanesulfonyl chloride 63 (0.68 mL, 8.8 mmol, 1.8 equiv) added dropwise *via* syringe. The resultant solution was allowed to warm to RT and stirred at RT for 36 h. The solvent was then removed *in vacuo*. The residue was dissolved in fresh DCM and water (25 mL) added to the solution. The solution was then extracted with DCM. The DCM extracts were washed with brine, and the brine back-extracted with DCM. The combined DCM extracts were then reduced *in vacuo* to yield a yellow oil (66, 0.88 g, quantitative).

Methanesulfonic acid tetrahydro-furan-2-yl methyl ester 70


10



Tetrahydrofurfuryl alcohol 69 (0.50 g, 4.9 mmol) was dissolved in dry DCM (30 mL) and triethylamine (1.06 mL, 8.8 mmol, 1.8 equiv) was added to the solution *via* syringe under N₂ with stirring. The solution was cooled to 0 °C and methanesulfonyl chloride 63 (0.68 mL, 8.8 mmol, 1.8 equiv) added dropwise *via* syringe to the cooled solution. The resultant solution was allowed to warm to RT and stirred at RT for 36 h. The solvent was then removed *in vacuo*. The residue was dissolved in fresh DCM and water (25 mL) added to the solution. The solution was then extracted with DCM. The DCM extracts were washed with brine, and the brine back-extracted with DCM. The combined DCM extracts were dried (MgSO₄), then reduced *in vacuo* to yield a yellow oil (70, 0.86 g, 98 %).


6-Decyl-2-(tetrahydro-furan-2-ylmethoxy)-furo[2,3-*d*]pyrimidine 71

25



26 (0.182 g, 1.086 mmol), potassium carbonate (0.182 g, 2.17 mmol, 2 equiv) and
 5 methanesulfonic acid tetrahydro-furan-2-ylmethyl ester **70** (0.186 g, 1.086 mmol) were
 suspended in dry DMF (5 mL) under N₂, and the reaction mixture heated to 100 °C with
 stirring under N₂ for 8 h. The solvent was removed *in vacuo*. The resultant residue was
 suspended in water (100 mL) and extracted with DCM (5 X 50 mL), then washed with
 brine. The combined DCM extracts were dried over MgSO₄, filtered, reduced *in vacuo*
 10 and purified by flash column chromatography in a carefully altered 0-5 % methanol/DCM
 solvent eluent gradient to yield 120 mg (32 %) of *the title compound 71* as a white solid.
¹H NMR (CDCl₃) δ 8.63 (s, 1H, 4-H), 6.39 (s, 1H, 5-H), 4.49-4.36 (m, 3H, THF-CH),
 4.03-3.94 (m, 1H, O-CH₂-THF), 3.91-3.84 (m, 1H, O-CH₂-THF), 2.79 (t, *J* = 7.4 Hz, 2H,
 1'-CH₂), 2.19-1.84 (m, 4H, THF-CH), 1.80-1.73 (m, 2H, CH₂), 1.38-1.31 (m, 14H, CH₂),
 15 0.93 (t, *J* = 6.4 Hz, 3H, CH₃); ¹³C NMR (CDCl₃) δ 168.8 (7a-C), 162.6 (2-C), 159.3 (6-C),
 150.9 (4-CH), 114.5 (4a-C), 99.5 (5-CH), 77.6 (THF-C), 70.1 (THF-C), 68.9 (O-1'-CH₂-
 THF), 32.3 (CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (2 X CH₂), 29.5 (CH₂), 28.8 (CH₂), 28.7
 (CH₂), 27.6 (CH₂), 26.1 (CH₂), 23.1 (CH₂), 14.6 (-CH₂CH₃).


20 **6-Decyl-3-(tetrahydro-furan-2-ylmethyl)-3H-furo[2,3-d]pyrimidin-2-one 72**



The title compound 72 (157 mg, 42 %) was also isolated from the reaction mixture as a white solid. ^1H NMR (CDCl_3) δ 7.95 (s, 1H, 4-H), 6.13 (s, 1H, 5-H), 4.55 (dd, $J = 2.3$, 13.6 Hz, 1H, N- CH_2 -THF), 4.29 (m, 1H, N- CH_2 -THF), 3.93-3.72 (m, 3H, THF-CH), 2.68 (t, $J = 7.4$ Hz, 2H, 1'- CH_2), 2.26-2.15 (m, 1H, THF-CH), 2.00-1.90 (m, 2H, CH_2), 1.71-1.63 (m, 3H, THF-CH), 1.37-1.31 (m, 14H, CH_2), 0.93 (t, $J = 6.4$ Hz, 3H, CH_3); ^{13}C NMR (CDCl_3) δ 172.4 (7a-C), 160.2 (2-C), 156.1 (6-C), 140.5 (4-CH), 107.9 (4a-C), 98.9 (5-CH), 77.3 (THF-C), 68.6 (THF-C), 54.9 (N-1'- CH_2 -THF), 32.3 (CH_2), 30.0 (CH_2), 29.9 (CH_2), 29.8 (CH_2), 29.7 (CH_2), 29.5 (CH_2), 29.2 (CH_2), 28.7 (CH_2), 27.2 (CH_2), 26.2 (CH_2), 23.1 (CH_2), 14.6 ($-\text{CH}_2\text{CH}_3$).

10


6-Decyl-2-(tetrahydro-pyran-2-ylmethoxy)-furo[2,3-*d*]pyrimidine 61



26 (0.30 g, 1.086 mmol), potassium carbonate (0.30 g, 2.17 mmol, 2 equiv) were suspended in dry DMF (5 mL) under N_2 , and 2-(bromomethyl)tetrahydro-2H-pyran 74 (0.28 mL, 2.17 mmol, 2 equiv) added *via* syringe with stirring under N_2 . The resultant mixture was heated to 110 $^\circ\text{C}$ with stirring overnight. The solvent was then removed *in vacuo* at 80 $^\circ\text{C}$, and the residue suspended in water (100 mL) and extracted with DCM (5 X 50 mL). The combined DCM extracts were washed with brine, dried over MgSO_4 , filtered, reduced *in vacuo* and purified slowly by flash chromatography in a DCM, then carefully altered 0-5 % methanol/DCM eluent gradient to yield the title compound 61 as a white solid (120 mg, 30 %) as a white solid. ^1H NMR (CDCl_3) δ 8.63 (s, 1H, 4-H), 6.38 (s, 1H, 5-H), 4.50-4.34 (m, 2H, O- CH_2 -THP), 4.08 (m, 1H, THP-CH), 3.83 (m, 1H, THP-CH), 3.54 (t, $J = 11.3$ Hz, 1H, THP-CH), 2.79 (t, $J = 7.4$ Hz, 2H, 1'- CH_2), 1.97-1.94 (m, 1H, THP-CH), 1.76 (app d, $J = 7.6$ Hz, 2H, CH_2), 1.39-1.31 (m, 16H, CH_2), 0.93 (t, $J = 6.5$ Hz, 3H, $-\text{CH}_2\text{CH}_3$); ^{13}C NMR (CDCl_3) δ 168.8 (7a-C), 162.6 (2-C), 159.3 (6-C), 150.9 (4-CH), 114.5 (4a-C), 99.5 (5-CH), 76.0 (THP-C), 71.3 (THP-C), 67.7 (1'- CH_2 -THP), 32.3

(CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.8 (CH₂), 29.7 (CH₂), 29.5 (CH₂), 28.8 (CH₂), 28.5 (CH₂), 27.6 (CH₂), 26.3 (CH₂), 23.5 (CH₂), 23.1 (CH₂), 14.6 (-CH₂CH₃).


5 **6-Decyl-3-(tetrahydro-pyran-2-ylmethyl)-3H-furo[2,3-d]pyrimidin-2-one 62**



- 10 Also isolated from the mixture was **62**, the title compound in 26 % yield (105 mg) as a white compound. ¹H NMR (CDCl₃) δ 7.84 (s, 1H, 4-H), 6.11 (s, 1H, 5-H), 4.48 (dd, *J* = 1.9, 6.7 Hz, 1H, N-CH₂-THP), 3.92 (app d, *J* = 10.7 Hz, 1H, THP-CH), 3.71 (m, 1H, THP-CH), 3.52 (app q, *J* = 4.5, 6.7 Hz, 1H, THP-CH), 3.38-3.30 (m, 1H, THP-CH), 2.66 (t, *J* = 7.4 Hz, 2H, 1'-CH₂), 1.97-1.94 (m, 1H, THP-CH), 1.88-1.47 (m, 4H, CH₂), 1.35-1.29 (m, 18H, CH₂), 0.91 (t, *J* = 6.5 Hz, 3H, -CH₂CH₃); ¹³C NMR (CDCl₃) δ 172.5 (7a-C), 160.0 (2-C), 156.1 (6-C), 141.1 (4-CH), 107.5 (4a-C), 98.9 (5-CH), 75.3 (THP-C), 68.7 (THP-C), 56.6 (1'-CH₂-THP), 32.3 (CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.8 (CH₂), 29.7 (CH₂), 29.5 (CH₂), 29.4 (CH₂), 28.7 (CH₂), 27.2 (CH₂), 26.3 (CH₂), 23.3 (CH₂), 23.1 (CH₂), 14.6 (-CH₂CH₃).

20

Methanesulfonic acid 3-methyl-cyclopentyl ester 76




3-Methylcyclopentanol **75** (0.5 g, 4.99 mmol) was dissolved in dry DCM (25 mL), and triethylamine (0.8 mL, 6.5 mmol, 1.3 equiv) added to the stirred solution under N₂, which was then cooled to 0 °C. Methanesulfonyl chloride (0.5 mL, 6.5 mmol, 1.3 equiv) was added dropwise via syringe to the chilled solution, the resultant solution warmed to

5 RT and allowed to react at RT with stirring for 36 h. The solvent was removed *in vacuo*, and the residue dissolved in water (50 mL), which was extracted with DCM (5 X 50 mL). The combined DCM extracts were washed with brine (which was back extracted with fresh DCM (25mL)), dried (MgSO₄), filtered and reduced under vacuum to yield a clear yellow oil (789 mg, 88 %).


10

6-Decyl-2-(4-methoxybenzyloxy)-3H-furo[2,3-*d*]pyrimidine Cf2315



15 6-Decyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one **26** (0.50 g, 1.81 mmol) and potassium carbonate (0.50 g, 3.62 mmol, 2 equiv.) were suspended in dry DMF (6 mL), and 4-methoxybenzyl chloride (0.5 mL, 3.62 mmol, 2 equiv) added to the stirred solution *via* syringe under N₂. The resultant mixture was heated with stirring to 120 °C overnight. The solvent were removed *in vacuo* at 80 °C, then the residue purified by flash column
20 chromatography in a 0-5 % MeOH/DCM eluent gradient to yield *the title compound X* (63 mg, 9 %) as a white solid. ¹H NMR (CDCl₃) δ 8.61 (s, 1H, H-4), 7.48 (d, *J* = 8.4 Hz, 2H, Ar-CH), 6.93 (d, *J* = 8.7 Hz, 2H, Ar-CH), 6.35 (s, 1H, H-5), 5.44 (s, 2H, Ph-CH₂), 3.82 (s, 3H, O-CH₃), 2.77 (t, *J* = 7.3 Hz, 2H, α-CH₂), 1.75 (qt, *J* = 7.3 Hz, 2H, CH₂), 1.40-1.29 (m, 14H, CH₂), 0.91 (t, *J* = 7.0 Hz, 3H, CH₃); ¹³C NMR (CDCl₃) δ 168.2 (7a-C), 159.6 (C-2),
25 159.3 (C-6), 149.9 (4-CH), 130.8 (Ar-CH), 129.7 (Ar-CH), 116.2 (Ar-CH), 114.3 (Ar-CH), 99.7 (5-CH), 69.7 (Ph-CH₂), 32.3 (α-CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 28.8 (CH₂), 27.6 (CH₂), 23.5 (CH₂), 21.1 (CH₂), 14.6 (CH₃).

6-Decyl-3-(4-methoxybenzyl)-3H-furo[2,3-d]pyrimidin-2-one Cf2316




5

Also obtained from the mixture was the *title compound* as a white solid **34** (312 mg, 44 %).

^1H NMR (CDCl_3) δ 7.70 (s, 1H, H-4), 7.35 (d, $J = 8.0$ Hz, 2H, Ar-CH), 6.95 (d, $J = 7.8$ Hz, 2H, Ar-CH), 6.06 (s, 1H, H-5), 5.18 (s, 2H, Ph-CH₂), 3.86 (s, 3H, O-CH₃), 2.66 (t, $J = 7.5$ Hz, 2H, α -CH₂), 1.69 (m, 2H, CH₂), 1.40-1.31 (m, 14H, CH₂), 0.93 (t, $J = 7.2$ Hz, 3H, CH₃); ^{13}C NMR (CDCl_3) δ 172.4 (7a-C), 160.6 (C-2), 155.8 (C-6), 138.1 (4-CH), 130.7 (Ar-CH), 128.5 (Ar-CH), 114.9 (Ar-CH), 108.2 (4a-C), 98.9 (5-CH), 55.7 (O-CH₃), 54.0 (Ph-CH₂), 32.3 (α -CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.4 (CH₂), 28.7 (CH₂), 27.2 (CH₂), 23.1 (CH₂), 14.6 (CH₃).


6-Decyl-2-(4-methylbenzyloxy)-3H-furo[2,3-d]pyrimidine Cf2313



6-Decyl-2,3-dihydrofuro[2,3-d]pyrimidin-2-one **26** (0.50 g, 1.81 mmol), potassium carbonate (0.50 g, 3.62 mmol, 2 equiv) were suspended in dry DMF (5 ml) and 4-methylbenzyl chloride (0.5 mL, 3.62 mmol, 2 equiv) added to the stirred suspension under N₂ via syringe. The resultant mixture was then heated at 100 °C overnight. The solvents were removed *in vacuo* at 80 °C and the resultant residue purified by flash column chromatography in a 0-5 % methanol/DCM eluent gradient to yield **30**, the *title product*

(105 mg, 15 %), as a white solid. ^1H NMR (CDCl_3) δ 8.64 (s, 1H, H-4), 7.45 (d, $J = 7.9$ Hz, 2H, Ar-CH), 7.21 (d, $J = 8.0$ Hz, 2H, Ar-CH), 6.40 (s, 1H, H-5), 5.49 (s, 2H, Ph-CH₂), 2.80 (t, $J = 7.4$ Hz, 2H, α -CH₂), 2.43 (s, 3H, Ar-CH₃), 1.79 (qt, $J = 6.8$ Hz, 2H, CH₂), 1.47-1.32 (m, 14H, CH₂), 0.94 (t, $J = 7.2$ Hz, 3H, CH₃); ^{13}C NMR (CDCl_3) δ 168.8 (7a-C), 162.2 (C-2), 159.3 (C-6), 149.9 (4-CH), 138.5 (Ar-CH), 129.5 (Ar-CH), 128.5 (Ar-CH), 114.3 (Ar-CH), 99.6 (5-CH), 69.6 (Ph-CH₂), 32.3 (α -CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.5 (CH₂), 28.8 (CH₂), 23.1 (CH₂), 21.7 (CH₂), 14.6 (CH₃).

6-Decyl-3-(4-methylbenzyl)-3H-furo[2,3-d]pyrimidin-2-one Cf2314




10

Also obtained from the mixture was the *title compound* 31 (440 mg, 65 %) as a white solid. ^1H NMR (CDCl_3) δ 7.71 (s, 1H, H-4), 7.30 (d, $J = 8.2$ Hz, 2H, Ar-CH), 7.23 (d, $J = 8.0$ Hz, 2H, Ar-CH), 6.05 (s, 1H, H-5), 5.20 (s, 2H, Ph-CH₂), 2.66 (t, $J = 7.4$ Hz, 2H, α -CH₂), 2.63 (s, 3H, Ar-CH₃), 1.73 (qt, $J = 7.6$ Hz, 2H, CH₂), 1.43-1.32 (m, 14H, CH₂), 0.92 (t, $J = 7.0$ Hz, 3H, CH₃); ^{13}C NMR (CDCl_3) δ 172.3 (7a-C), 160.6 (C-2), 156.2 (C-6), 138.9 (4-CH), 132.8 (Ar-CH), 129.2 (Ar-CH), 128.5 (Ar-CH), 114.3 (Ar-CH), 98.8 (5-CH), 54.2 (Ph-CH₂), 32.3 (α -CH₂), 30.0 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.4 (CH₂), 28.7 (CH₂), 27.1 (CH₂), 23.1 (CH₂), 21.6 (CH₃), 14.6 (CH₃).


20

6-Hexyl-2,3-dihydrofuro[2,3-d]pyrimidin-2-one



5-Iodouracil **23** (5.00 g, 21 mmol), tetrakis(triphenylphosphine)palladium(0) (1.0 g, 0.87 mmol, 0.04 equiv), and copper iodide (0.80 g, 4.2 mmol, 0.2 equiv) were dissolved in dry DMF (50 mL) with stirring under N₂. DIPEA (7.3 mL, 5.42 g, 42 mmol, 2 equiv), then 1-octyne (9.3 mL, 6.93 g, 63 mmol, 3 equiv) were added sequentially to the solution *via* syringe and the resultant solution, which darkened from golden to dark green over 20 min, left to stir at RT for 18 h. A further addition of copper iodide (0.80 g) was then made, followed by triethylamine (25 mL) and the resultant suspension heated at 120 °C for 6 h. The suspension was allowed to cool, the volume of solvent reduced to *ca.* 20 mL, and the solid collected by filtration, washed with DCM and methanol to yield a grey powder of weight 3.13 g (**38**, 68 %). ¹H NMR (CDCl₃) δ 12.23 (br, 1H, NH), 8.16 (br, 1H, H-4), 6.38 (br, 1H, H-5), 2.65 (t, *J* = 7.1 Hz, 2H, α-CH₂), 1.63 (qt, *J* = 7.4 Hz, 2H, CH₂), 1.31 (m, 6H, CH₂), 0.88 (t, *J* = 6.4 Hz, 3H, CH₃).


6-Hexyl-3-methyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2344



6-Hexyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one **38** (0.40 g, 1.82 mmol) and potassium carbonate (0.50 g, 3.64 mmol, 2 equiv) were suspended in dry DMF (5 mL) under N₂ and methyl iodide (0.23 mL, 3.64 mmol, 2 equiv) added *via* syringe to the stirred suspension, which was then heated to 80 °C overnight. The solvents were removed *in vacuo* and the crude purified by flash column chromatography in a 0-5% MeOH/DCM solvent gradient to yield *the title product* **40** as a white solid in very low yield (25 mg, 6 %). ¹H NMR (CDCl₃) δ 7.76 (s, 1H, H-4), 6.04 (s, 1H, H-5), 3.59 (s, 3H, N-CH₃), 2.59 (t, *J* = 7.5 Hz, 2H, α-CH₂), 1.63 (qt, *J* = 7.4 Hz, 2H, CH₂), 1.35-1.20 (m, 6H, CH₂), 0.83 (t, *J* = 7.0 Hz, 3H, CH₃); ¹³C NMR (CDCl₃), δ 172.5 (7a-C), 160.5 (C-2), 156.4 (C-6), 139.5 (4-CH),

108.3 (4a-C), 98.6 (5-CH), 40.2 (N-CH₃), 31.8 (α -CH₂), 29.1 (CH₂), 28.7 (CH₂), 27.1 (CH₂), 22.9 (CH₂), 14.5 (CH₃).

2-Butyloxy-6-hexyl-furo[2,3-*d*]pyrimidine Cf2346



5


6-Hexyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one **38** (0.40 g, 1.82 mmol), potassium carbonate (0.50 g, 3.65 mmol, 2 equiv) and 1-iodobutane (0.41 mL, 3.62 mmol, 2 equiv) were suspended in dry DMF (5 mL) under N₂ and heated to 80 °C with stirring overnight. The solvents were removed *in vacuo* and the crude purified by flash column
10 chromatography in a 0-5% MeOH/DCM solvent gradient to yield *the title product 42* as a white solid (180 mg, 36 %). ¹H NMR (CDCl₃) δ 8.65 (s, 1H, H-4), 6.34 (s, 1H, H-5), 4.42 (t, *J* = 6.6 Hz, 2H, O-CH₂-), 2.77 (t, *J* = 7.5 Hz, 2H, α -CH₂), 1.86 (qt, *J* = 7.5 Hz, 2H, CH₂), 1.76 (qt, *J* = 7.5 Hz, 2H, CH₂), 1.55 (m, 2H, CH₂), 1.43-1.31 (m, 6H, CH₂), 1.00 (t, *J* = 7.2 Hz, 3H, CH₃), 0.92 (t, *J* = 6.8 Hz, 3H, CH₃); ¹³C NMR (CDCl₃) δ 168.8 (7a-C),
15 162.8 (C-2), 159.1 (C-6), 150.8 (4-CH), 99.6 (5-CH), 68.1 (O-CH₂-), 31.9 (α -CH₂), 31.3 (CH₂), 31.2 (CH₂), 29.1 (CH₂), 28.8 (CH₂), 27.6 (CH₂), 22.9 (CH₂), 19.6 (CH₂), 14.5 (CH₃), 14.2 (CH₃).

2-Benzoyloxy-6-hexyl-furo[2,3-*d*]pyrimidine Cf2348

20 6-Hexyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one (**44**, 0.40 g, 1.82 mmol) and potassium carbonate (0.50 g, 3.64 mmol, 2 equiv) were added under N₂ to dry DMF (5 mL), and the resultant suspension charged with benzyl chloride **43** (0.42 mL, 3.64 mmol, 2 equiv), then heated to 80 °C overnight. The solvents were removed *in vacuo* and the crude purified by flash column chromatography in a 0-5% MeOH/DCM eluent gradient to yield 39 mg (**44**, 7
25 %) of *the title compound* as a white solid. ¹H NMR (CDCl₃) δ 8.65 (br, 1H, H-4), 7.57 (d, *J* = 7.4 Hz, 2H, Ar-CH), 7.46-7.36 (m, 3H, Ar-CH), 6.38 (s, 1H, H-5), 5.53 (s, 2H, Ph-CH₂), 2.81 (t, *J* = 7.6 Hz, 2H, α -CH₂), 1.79 (qt, *J* = 7.4 Hz, 2H, CH₂), 1.47-1.33 (m, 6H,

CH_2), 0.95 (t, $J = 6.8$ Hz, 3H, CH_3); ^{13}C NMR (CDCl_3) δ 168.8 (7a-C), 162.5 (C-2), 159.4 (C-6), 150.9 (4-CH), 137.0 (Ar-C), 128.8 (Ar-C), 128.4 (Ar-C), 128.3 (Ar-C), 113.9 (4-CH), 99.6 (Ar-C), 69.7 (O- CH_2 -Ph), 31.9 (α - CH_2), 29.1 (CH_2), 28.7 (CH_2), 27.1 (CH_2), 23.0 (CH_2), 14.5 (CH_3).

5 **3-Benzyl- 6-hexyl-3H-furo[2,3-d]pyrimidin-2-one Cf2349**



Also obtained from the purification process was *the title compound 45* as a white solid
 10 (391 mg, 69 %). ^1H NMR (CDCl_3) δ 7.89 (s, 1H, H-4), 7.49 (m, 5H, Ar-CH), 6.19 (s, 1H, H-5), 5.39 (s, 2H, Ph- CH_2), 2.76 (t, $J = 7.4$ Hz, 2H, α - CH_2), 1.80 (qt, $J = 7.4$ Hz, 2H, CH_2), 1.54-1.38 (m, 6H, CH_2), 1.02 (t, $J = 6.8$ Hz, 3H, CH_3); ^{13}C NMR (CDCl_3) δ 172.2 (7a-C), 160.7 (C-2), 156.1 (C-6), 138.5 (Ar-C), 136.0 (Ar-C), 129.5 (2 x Ar-C), 129.0 (Ar-C), 128.9 (Ar-C), 108.6 (4-CH), 98.9 (5-CH), 54.5 (N- CH_2 -Ph), 31.8 (α - CH_2), 29.1 (CH_2),
 15 28.7 (CH_2), 27.1 (CH_2), 22.9 (CH_2), 14.5 (CH_3).

Biological Activity

Products where $\text{X}=\text{Y}=\text{N}$, $\text{Z}=\text{Q}=\text{O}$, $\text{U}=\text{V}=\text{CH}$ and R^1 , R^4 and R^8 are as given in Tables 1
 20 and 2 below embodying the present invention were tested *in vitro* in tissue cultures for toxicity and for potent antiviral actions with respect to cytomegalovirus (CMV). The results are given in Tables 1 and 2 below.

The column headings in Tables 1 and 2 are as follows:

25

R^1 , R^4 and R^8 are as defined with respect to formula I above.

EC₅₀/μm CMV-AD169 is the drug concentration in μM required to reduce by 50% CMV strain AD169 induced cytopathicity in human embryonic lung fibroblast (HEL) cells measured 7 days post infection compared to untreated control.

- 5 EC₅₀/μM CMV Davis is the drug concentration in μM required to reduce by 50% CMV strain Davis induced cytopathicity in human embryonic lung fibroblast (HEL) cells measured 7 days post infection compared to untreated control.

CC₅₀/μM is the compound concentration required to reduce the cell number by 50%.


10

Further details of the methodology employed can be found in McGuigan *et al.* J. Med.Chem., 1999, 42, 4479-4484.

15

20


Table 1



No.	R ¹	R ⁸	EC ₅₀ /μM		CC ₅₀ /μM
			CMV AD169	1 CMV Davis	
2158	nC ₄ H ₉	Cyclo C ₅ H ₉	>50	>50	ND
2160	nC ₇ H ₁₅	Cyclo C ₅ H ₉	5	4	194
2194	nC ₄ H ₉	CH(Et) ₂	>50	>200	>200
2190	nC ₇ H ₁₅	CH(Et) ₂	20	50	>200
2195	nC ₄ H ₉	nC ₅ H ₁₁	>50	>50	>200
2192	nC ₇ H ₁₅	nC ₅ H ₁₁	>200	>200	>200
2196	nC ₇ H ₁₅	2-THF	>20	>20	46
2249	nC ₁₀ H ₂₁	2-THF	>50	50	>200
2275	nC ₁₀ H ₂₁	CH ₂ Cyclo C ₆ H ₁₁	>200	>200	>200
2276	nC ₁₀ H ₂₁	3-THF	20	10	148
2295	nC ₁₀ H ₂₁	Cyclo C ₆ H ₁₁	38	50	>200
2304	nC ₁₀ H ₂₁	C ₃ H ₇	40	8	>200
2306	nC ₁₀ H ₂₁	nC ₄ H ₉	>200	>200	>200
2308	nC ₁₀ H ₂₁	PhCH ₂	>40	>40	>200
2314	nC ₁₀ H ₂₁	TolCH ₂	>40	>40	>200
2316	nC ₁₀ H ₂₁	pMeOPhCH ₂	>200	>200	>200
2309	nC ₁₀ H ₂₁	CH ₂ Cyclo C ₅ H ₉	0.78	0.84	49
2344	nC ₆ H ₁₃	Me	18	20	ND

2345	nC ₆ H ₁₃	nC ₃ H ₇	20	20	ND
2347	nC ₆ H ₁₃	nC ₄ H ₉	19	20	ND
2349	nC ₆ H ₁₃	PhCH ₂	>200	>200	ND

Table 2




5

No.	R ¹	R ⁴	EC ₅₀ /μM		CC ₅₀ /μM
			CMV AD169	2 CMV Davis	
2159	nC ₄ H ₉	Cyclo C ₅ H ₉	8	7	108
2161	nC ₇ H ₁₅	Cyclo C ₅ H ₉	3	5	132
2193	nC ₄ H ₉	CH(Et) ₂	>20	>20	98
2189	nC ₇ H ₁₅	CH(Et) ₂	>5	12	98
2191	nC ₇ H ₁₅	nC ₅ H ₁₁	>5	16	1109
2247	nC ₁₀ H ₂₁	nC ₅ H ₁₁	>200	>200	>200
2250	nC ₁₀ H ₂₁	Cyclo C ₅ H ₉	>50	>50	>200
2252	nC ₁₀ H ₂₁	CH(Et) ₂	16	10	127
2294	nC ₁₀ H ₂₁	Cyclo C ₆ H ₁₁	12	16	>200
2303	nC ₁₀ H ₂₁	nC ₃ H ₇	2.5	2.1	126
2305	nC ₁₀ H ₂₁	nC ₄ H ₉	3.9	2.7	>200
2307	nC ₁₀ H ₂₁	PhCH ₂	3.3	1.1	>200
2274	nC ₁₀ H ₂₁	CH ₂ CycloC ₆ H ₁₁	4.4	2.9	>200
2313	nC ₁₀ H ₂₁	TolCH ₂	10.5	3.9	>200
2315	nC ₁₀ H ₂₁	pMeOPhCH ₂	3.3	2.9	>200

2343	nC_6H_{13}	Me	>8	4.7	ND
2346	nC_6H_{13}	nC_4H_9	8	3	ND
2348	nC_6H_{13}	PhCH ₂	>200	>3.6	ND

CLAIMS

1. A chemical compound having the formula (I):



5 wherein:

R^1 and R^4 are independently selected from alkyl, aryl, alkenyl and alkynyl;

10 Z is selected from O, NH, S, Se, NR^5 and $(CH_2)_n$ where n is 1 to 10, and CT_2 where T may be the same or different and is selected from hydrogen, alkyl and halogens, and R^5 is alkyl, alkenyl or aryl;

Y is selected from N, CH and CR^6 where R^6 is alkyl, alkenyl, alkynyl or aryl;

15 Q is selected from O, S, NH, N-alkyl, CH_2 , CHalkyl and $C(alkyl)_2$;

U is selected from N and CR^2 , R^2 is selected from hydrogen, alkyl, halogen, amino, alkylamino, dialkylamino, nitro, cyano, alkoxy, aryloxy, thiol, alkylthiol, arylthiol and aryl;

20

V is selected from N and CR^3 , where R^3 is selected from hydrogen, alkyl, halogens, alkyloxy, aryloxy and aryl; and

25 when a double bond exists between X and the ring atom to which Q is attached and Q is linked to the ring moiety by a single bond, X is selected from N, CH and CR^7 , where R^7 is selected from alkyl, alkenyl, alkynyl and aryl; and

- when a double bond links Q to the ring moiety and a single bond exists between X and the ring atom to which Q is attached, R^4 does not exist and X is NR^8 , where R^8 is alkyl, alkenyl, alkynyl or aryl, except that when Y is N, R^8 is not an alkyl or alkenyl group substituted at the fourth atom of the chain of said alkyl or alkenyl group, counted along the shortest route away from the ring moiety including any heteroatom present in said chain, by a member selected from OH, phosphate, diphosphate, triphosphate, phosphonate, diphosphonate, triphosphonate and pharmacologically acceptable salts, derivatives and prodrugs thereof;
- 10 and pharmacologically acceptable salts, derivatives and prodrugs of compounds of formula I.
2. A compound according to claim 1 wherein when a double bond exists between X and the ring atom to which Q is attached, X and Y are both N.
- 15 3. A compound according to claim 1 or claim 2 wherein when a double bond exists between X and the ring atom to which Q is attached, Z is O or NH, preferably O.
4. A compound according to any one of claims 1 to 3 wherein when a double bond exists between X and the ring atom to which Q is attached, Q is O.
- 20 5. A compound according to claim 1 wherein X and Y are N, Q and Z are independently selected from O, S and NH, and preferably both Q and Z are O.
- 25 6. A compound according to any one of claims 1 to 5 wherein each of U and V is CH.
7. A compound according to any one of claims 1 to 6 wherein R^1 is selected from C_{3-20} alkyl, C_{3-20} cycloalkyl, C_{3-20} alkenyl, C_{3-20} alkynyl, C_{5-14} aryl and C_{1-10} alkyl C_{5-14} aryl, preferably C_{3-14} alkyl, C_{3-14} alkenyl and C_{3-14} alkynyl, more preferably C_{8-10} alkyl, C_{8-10} alkenyl and C_{8-10} alkynyl.
- 30 8. A compound according to claim 7 wherein R^1 is unbranched and unsubstituted C_{3-12} alkyl, preferably C_{6-10} alkyl.

9. A compound according to anyone of claims 1 to 7 wherein each of R^4 and R^8 is selected from C_{1-12} alkyl, C_{1-12} alkenyl, C_{1-12} alkynyl, C_{3-12} cycloalkyl, C_{1-6} alkyl substituted with C_{3-7} cycloalkyl, C_{1-3} alkyl, C_{5-14} aryl and C_{3-6} cycloalkyl and C_{5-14} aryl containing 1, 2, 3 or 4 hetero ring-atoms independently selected from O, N and S, preferably R^4 and R^8 are selected from C_{1-10} alkyl, C_{1-10} alkenyl and C_{1-10} alkynyl.
10. A compound according to any one of claims 1 to 8 wherein R^1 is C_{3-14} alkyl, C_{3-14} alkenyl or C_{3-14} alkynyl, preferably C_{6-14} alkyl, C_{6-14} alkenyl or C_{6-14} alkynyl, and R^4 and R^8 are selected from C_{1-12} alkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl substituted with C_{3-7} cycloalkyl, preferably C_{5-6} alkyl or C_{5-6} cycloalkyl.
11. A compound according to one of claims 1 to 9 wherein R^1 is C_{10} alkyl.
12. A compound according to any one of claims 1 to 11 wherein R^4 and R^8 are selected from benzyl or substituted benzyl.
13. A compound according to any one of claims 1 to 10 wherein R^4 and R^8 are C_1 alkyl substituted with C_{1-10} cycloalkyl, preferably C_1 alkyl substituted with C_{5-6} cycloalkyl.
14. A compound according to claim 1 wherein X and Y are both N, U and V are both CH, Z and Q are independently selected from O, S and NH, and each of R^1 , R^4 and R^8 are C_{8-12} alkyl.
15. A compound selected from the group comprising:
- 6-Butyl-3-cyclopentyl-3H-furo[2,3-d]pyrimidin-2-one (139) [Cf2158]
 - 6-Butyl-2-cyclopentyloxy-furo[2,3-d]pyrimidin (130) [Cf2159]
 - 6-Heptyl-3-cyclopentyl-3H-furo[2,3-d]pyrimidin-2-one (140) [Cf2160]
 - 6-Heptyl-2-cyclopentyloxy-furo[2,3-d]pyrimidin (141) [Cf2161]
 - 6-Butyl-3-(1-ethyl-propyl)-3H-furo[2,3-d]pyrimidin-2-one (142) [Cf2194]
 - 6-Butyl-2-(1-ethyl-propoxy)-furo[2,3-d]pyrimidine (143) [Cf2193]

- 6-Heptyl-3-(1-ethyl-propyl)-3*H*-furo[2,3-*d*]pyrimidin-2-one (144) [Cf2190]
- 6-Heptyl-2-(1-ethyl-propoxy)-furo[2,3-*d*]pyrimidine (145) [Cf2189]
- 6-Butyl-3-pentyl-3*H*-furo[2,3-*d*]pyrimidin-2-one (146) [Cf2195]
- 6-Butyl-2-pentyloxy-furo[2,3-*d*]pyrimidine (147) [Cf2327]
- 5 6-Heptyl-3-pentyl-3*H*-furo[2,3-*d*]pyrimidine-2-one (148) [Cf2192]
- 6-Heptyl-3-pentyloxy-3*H*-furo[2,3-*d*]pyrimidin-2-one (149) [Cf2191]
- 6-Heptyl-3-(tetrahydro-furan-2-yl)-3*H*-furo[2,3-*d*]pyrimidin-2-one (154) [Cf2196]
- 6-Decyl-2-propoxy-furo[2,3-*d*]pyrimidine Cf2303
- 6-Decyl-3-propyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2304
- 10 2-Butoxy-6-decyl-furo[2,3-*d*]pyrimidine Cf2305
- 3-Butyl-6-decyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2306
- 6-Decyl-2-pentyloxy-2,3-dihydrofuro[2,3-*d*]pyrimidine Cf2247
- 2-Cyclopentyloxy-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidine Cf2250
- 3-Cyclopentyl-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one Cf2251
- 15 2-(1'-Ethyl-propyloxy)-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidine Cf2252
- 3-(1'-Ethyl-propyl)-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one Cf2253
- 2-Cyclohexyloxy-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidine Cf2294
- 3-Cyclohexyl-6-decyl-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one Cf2295
- 6-Decyl-3-(tetrahydro-furan-2-ylmethyl)-3*H*-furo[2,3-*d*]pyrimidin-2-one 72
- 20 Cf2309
- 2-Cyclohexylmethoxy-6-decyl-furo[2,3-*d*]pyrimidine Cf2274

3-Cyclohexylmethyl-6-decyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2275

2-Benzoyloxy-6-decyl-furo[2,3-*d*]pyrimidine Cf2307

3-Benzyl-6-decyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2308

6-Decyl-3-(tetrahydro-furan-2'-yl)-2,3-dihydrofuro[2,3-*d*]pyrimidin-2-one

5 Cf2249

6-Decyl-2-(tetrahydro-furan-3-yloxy)-furo[2,3-*d*]pyrimidine 58

6-Decyl-3-(tetrahydro-furan-3-yl)-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2276

6-Decyl-2-(tetrahydro-furan-2-ylmethoxy)-furo[2,3-*d*]pyrimidine 71

6-Decyl-3-(tetrahydro-furan-2-ylmethyl)-3*H*-furo[2,3-*d*]pyrimidin-2-one 72

10 6-Decyl-2-(tetrahydro-pyran-2-ylmethoxy)-furo[2,3-*d*]pyrimidine 61

6-Decyl-3-(tetrahydro-pyran-2-ylmethyl)-3*H*-furo[2,3-*d*]pyrimidin-2-one 62

6-Decyl-2-(4-methoxybenzyloxy)-3*H*-furo[2,3-*d*]pyrimidine Cf2315

6-Decyl-3-(4-methoxybenzyl)-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2316

6-Decyl-2-(4-methylbenzyloxy)-3*H*-furo[2,3-*d*]pyrimidine Cf2313

15 6-Decyl-3-(4-methylbenzyl)-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2314

6-Hexyl-3-methyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2344

2-Butyloxy-6-hexyl-furo[2,3-*d*]pyrimidine Cf2346

2-Benzoyloxy-6-hexyl-furo[2,3-*d*]pyrimidine Cf2348

3-Benzyl-6-hexyl-3*H*-furo[2,3-*d*]pyrimidin-2-one Cf2349

20 16. A method for preparing compounds according to any one of claims 1 to 15 wherein a 5-halo nucleoside analogue is contacted with a terminal alkyne in the presence of a catalyst, or a 5-alkynyl nucleoside is cyclised in the presence of a catalyst.

17. A compound according to any one of claims 1 to 15 for use in a method of treatment.
18. Use of a compound according to any one of claims 1 to 15 in the manufacture of a medicament for the prophylaxis or treatment of viral infection.
- 5 19. Use according to claim 18 wherein the viral infection is a cytomegalovirus viral infection.
20. A method of prophylaxis or treatment of viral infection comprising administration to a patient in need of such treatment an effective dose of a compound according to any of claims 1 to 15.
- 10 21. A method according to claim 20 wherein the viral infection is a cytomegalovirus viral infection.
22. A compound according to any one of claims 1 to 15 in the manufacture of a medicament for use in the prophylaxis or treatment of a viral infection.
23. A compound according to claim 22 wherein the viral infection is a cytomegalovirus
15 viral infection.
24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15 in combination with a pharmaceutically acceptable excipient.
25. A method of preparing a pharmaceutical composition comprising the step of combining a compound according to any one of claims 1 to 15 with a pharmaceutically
20 acceptable excipient.

PCT/GB2004/001687



This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**